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ABSTRACT 
Diagnosis of ovarian carcinoma is in urgent need for new complementary 
biomarkers for early stage detection. In order to find an alternative procedure to replace an 
uncomfortable conventional method in detecting cervical cancer, a proteomic approach in 
screening the urinary proteins were employed. Proteins that are aberrantly excreted in the 
urine of cancer patients are excellent biomarker candidates for development of new non-
invasive protocol for early diagnosis and screening purposes. In the present study, urine 
samples from patients with ovarian carcinoma and cervical cancer were analysed by two-
dimensional gel electrophoresis (2-DE) and the profiles generated were compared to those 
similarly obtained from age-matched cancer negative women. These samples were also 
subjected to SELDI-TOF-MS as a complimentary technique for 2-DE especially on 
screening of aberrantly expressed of low molecular weight proteins. 
Significant reduced levels of CD59, kininogen-1 and a 39 kDa fragment of inter-
alpha-trypsin inhibitor heavy chain H4 (ITIH4), and enhanced excretion of a 19 kDa 
fragment of albumin, were detected in the urine of patients with ovarian carcinoma 
compared to the control subjects. These proteins, with exception of kininogen-1, were also 
detected in the urine of patients with cervical cancer as compared to the control subjects. 
The different altered levels of the proteins were confirmed by Western blotting using 
antisera and a lectin that bind to the respective proteins. When the samples were analysed 
with SELDI-TOF-MS, one protein peak with m/z of 15802 was detected in ovarian cancer 
cohort, but not in cervical cancer and control. The peaks m/z 7528.78 and m/z 8828.8 were 
found to be significantly absent in ovarian cancer and cervical cancer, respectively. 
Interestingly, protein peak at m/z 15802 with a p-value less than 0.05 had a potential to be a 
good biomarker with 100% sensitivity and 89.4% specificity for the learning set obtained 
from the classification tree in the Biomarker Pattern Software (BPS). 
  /ABSTRACT/ 
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This study clearly demonstrated that the combined technology of 2-DE and SELDI-
TOF-MS is effective in distinguishing urinary protein expression between control, ovarian 
carcinoma and cervical cancer cohorts. The identified proteins CD59, kininogen-1 and 
fragments of ITIH4 and albumin may be used as complementary biomarkers in the 
development of new non-invasive protocols for diagnosis and screening of ovarian 
carcinoma and cervical cancer. The identified peaks may be candidate biomarkers for early 
detection and could be utilised to distinguish between ovarian and cervical cancer in the 
future. Furthermore, the classification tree generated by the Biomarker Pattern Software 
(BPS), has a potential to be used in classifying the three cohorts. 
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ABSTRAK 
 Penanda pelengkap biologi bagi ujian diagnosis kanser ovari diperlukan dengan 
segera terutama bagi pengesanan peringkat awal penyakit ini. Bagi mengganti prosedur 
konvensional yang tidak menyelesakan dalam mengecam kanser servik, perkembangan dari 
kaedah lain seperti pendekatan proteomik dalam saringan terhadap protein di dalam air 
kencing dilakukan.  Protein yang dikumuhkan secara aberan dalam air kencing penyakit 
kanser merupakan calon penanda biologi yang sangat baik dalam membangunkan protokol 
baru yang tidak invasif untuk diagnosis awal dan tujuan pemeriksaan. Dalam kajian ini, 
sampel air kencing daripada pesakit dengan karsinoma ovari dan kanser pangkal rahim 
telah dianalisis oleh elektroforesis gel dua dimensi (2-DE) dan profil yang dijana 
dibandingkan dengan wanita kontrol yang mempunyai padanan umur yang sama. Sampel 
ini juga telah digunakan dalam analisa menggunakan SELDI-TOF-MS sebagai teknik 
komplimentari bagi 2-DE terutama bagi saringan berat molekul protein rendah yang aberan.  
Tahap CD59, kininogen-1, serpihan 39 kDa alpha-trypsin inhibitor heavy chain H4 
(ITIH4) yang didapati berkurang secara signifikan, serta peningkatan serpihan 19 kDa 
albumin telah dikesan dalam air kencing pesakit karsinoma ovari berbanding wanita 
kontrol. Protein-protein tersebut kecuali kininogen-1 ini juga dikesan dalam air kencing 
kanser servik apabila dibandingkan dengan wanita kontrol. Tahap protein yang berbeza dari 
kebiasaan di dalam air kencing telah disahkan oleh kaedah Western blotting dengan 
menggunakan antisera dan lektin yang mengikat protein masing-masing. Apabila sampel 
dianalisa dengan SELDI-TOF-MS, satu puncak protein pada m/z 15802 dikesan dalam 
pesakit kanser ovari tetapi tidak  di dalam kanser servik dan wanita kontrol. Puncak protein 
pada m/z 7528.78 dan m/z 8828.8 didapati tiada secara signifikan di dalam kedua-dua jenis 
kanser. Apa yang menarik ialah, puncak pada m/z 15802 dengan p-value kurang dari 0.05 
mempunyai potensi untuk menjadi penanda bio yang baik dengan pencapaian 100% sensitif 
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dan 89.4% spesifik dari set pembelajaran yang diperoleh melalui kaedah klasifikasi di 
dalam Perisian Corak Biomarker (BPS).  
Kajian ini jelas menunjukkan bahawa gabungan teknologi 2-DE dan SELDI-TOF-
MS berkesan dalam memprofilkan protein yang berbeza dalam air kencing wanita kontrol, 
karsinoma ovari dan kanser servik. Protein CD59, kininogen-1, serpihan ITIH4 dan 
serpihan albumin dikenalpasti boleh digunakan sebagai pelengkap penanda biologi dalam 
pembangunan protokol baru yang tidak invasif bagi tujuan diagnosis dan pemeriksaan 
karsinoma ovari atau kanser pangkal rahim. Puncak protein yang dikenalpasti juga boleh 
dipertimbangkan sebagai calon protein bagi pengesanan awal dan membezakan antara 
karsinoma ovari dan kanser pangkal rahim pada masa akan datang. Tambahan juga, pokok 
klasifikasi yang dihasilkan oleh Perisian Corak biomarker (BPS), mempunyai potensi untuk 
digunakan dalam mengklasifikasikan ketiga kohort yang dikaji.
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1.1 Female reproductive system  
The purpose of the male and female reproductive systems is to continue the human 
species by the production of offspring. This is achieved through production of gametes, that 
is, sperm and egg cells, and ensures the union of gametes in fertilization following sexual 
intercourse (Scanlon & Sanders, 2007). 
The female reproductive organs found inside the body includes the vagina, uterus, 
ovaries, and fallopian tubes (Figure 1). The uterus can be divided into two parts called 
cervix and corpus. The cervix is the lower part of the uterus that opens into the vagina 
whereas the corpus is at the upper part where the structure can easily expand to hold a 
developing baby (Chung, 2000). A channel through the cervix allows sperm to enter and 
menstrual blood to exit. The ovaries are oval-shaped glands that are located on either side 
of the uterus. The ovaries produce eggs (ova) and also main female sex hormones which are 
released into the bloodstream (MacLennan et al., 1991). The clitoris, labia and a numeral of 
glands are all together known as vulva which is part of vagina that is found externally.  
According to the American Academy of Pediatrics, American College of 
Obstetricians and Gynecologists in 2006, the length of the reproductive or also known as 
menstrual cycle is usually 24-35 days. The main function of the female reproductive system 
is to give women the ability to produce ova to be fertilised, space and conditions for a fetus 
to grow. This female reproductive system is important to allow sperm from a man to meet 
the ova of a woman during the sexual intercourse. The lining of the uterus is prepared to 
receive a fertilised egg during the time where the ova is developed and matured. It is shed 
and expelled from the body if a fertilised egg is not implanted into the uterus. This bleeding 
process is also known as menstruation.  
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Figure 1: Location of the female reproductive system in women  
(Adapted with permission from http://emedicine.medscape.com assessed on 1 February 
2012) 
 
Anterior view 
Saggital section 
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1.1.1 Hormones in female reproductive cycle 
The activity of the female reproductive system is controlled by hormones released 
by the brain and the ovaries. There are five main hormones that control the reproductive 
cycle such as gonadotrophin-releasing hormone (GnRH), follicle-stimulating hormone 
(FSH), luteinizing hormone (LH), oestrogen and progesterone (Lobo, 2007). There are 
around 20 immature ova begin to develop in the ovaries during the last few days of the 
menstrual cycle (MacLennan et al., 1991). FSH and LH encourage the growth of these ova 
and as they grow, the ova also start to release increasing amount of oestrogen. The amount 
of oestrogen produced reduces the amount of FSH released which also prevents too many 
ova growing at the same time. As this is happening in the ovaries, the estrogen produced 
also stimulates the repair of the lining uterus. 
The mature ovum from the ovary is then released into the pelvis. At this moment in 
the cycle, oestrogen levels are high. Previously, medium level of oestrogen reduced the 
amount of FSH and LH released. The high level of oestrogen is the signal for more FSH 
and LH to be released. LH causes the ovum to burst through the outer layer of the ovary 
where then the ovum is swept into the uterine tubes (Losos et al., 2002). The cells 
remaining when the ovum leaves the ovary become the corpus luteum. This group of cells 
is able to produce several different hormones including progesterone and oestrogen 
(Weschler, 2002). These hormones encourage the growth and maturation of the lining of 
the uterus. 
The next event will depends whether the ovum is fertilised by a sperm. If the ovum 
is fertilised, the corpus luteum will continue to produce hormone. A hormone called human 
chorionic gonadotropin (hCG) is produced by the cells covering the embryo will stop the 
corpus luteum from breaking down (Tay et al., 2000). This is the hormone detected in the 
pregnancy test kit (Waddell et al., 2006). If the ovum is not fertilized, the corpus luteum 
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can only live for another two weeks. It releases less of its hormones as it begins to 
breakdown. The levels of GnRH, FSH and LH are no longer being controlled as the levels 
of progesterone and oestrogen go down. Thus, these hormones increase and new ova begin 
to develop, which means the starting of a new cycle. In the uterus, the decrease in 
progesterone stimulates the release of chemicals that eventually cause the lining of the 
uterus to die off. This is the blood flow experienced during menstruation. This process will 
happen over and over again until women start experiencing menopause (Losos et al., 2002). 
Any disturbance that occurred in the female reproductive system can lead to variety of 
disorders including infection, disorder of menstruation, pain (Sperrof, 2005) and 
malignancies. Figure 2 displays the location of the ovarian and cervical cancer that occurrs 
in the female reproductive system. 
 
1.2 Ovarian carcinoma  
Gynaecological cancer is a group of cancers that affect the tissues and organs of the 
female reproductive system. Each type of cancer is named after the organ it originates and 
they includes cervical cancer, ovarian cancer, uterine cancer, vaginal cancer and vulvar 
cancer (Lisa, 2010). Ovarian cancer is the fourth most common cancer affecting women in 
Malaysia (Lim et al., 2003). A critical factor in the elevated mortality associated with 
ovarian cancer is the lack of disease-specific symptoms. 
Although the cure rate for stage Ι disease is usually greater than 90%, the five year 
survival rate for patients with clinically advanced ovarian cancer is only 15-20% 
(Holschneider et al., 2000). Therefore, improved screening methodologies aimed at 
detecting ovarian cancer at its earliest stage have the potential to result in considerable 
improvement in overall survival of this disease.  
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Ovarian carcinoma 
 
     
         Cervical cancer 
Figure 2: Ovarian carcinoma and cervical cancer  
(Adapted with permission from http://www.medicinenet.com accessed on 1 February 2012) 
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1.2.1 Types of ovarian tumours and the risk factors 
Ovarian tumours are named according to the type of cells the tumour develops from. 
Mainly there are three types of ovarian cancers which are the epithelial tumours, germ cell 
tumours and stromal tumours (Andrew & Jules, 2011). The epithelial ovarian tumours can 
be divided further into benign epithelial ovarian tumours, tumour of low malignant 
potential, malignant epithelial ovarian tumours and primary peritoneal carcinoma. The 
germ cell tumours can also be further categorised into teratoma, dysgerminoma, 
endodermal sinus tumour (yolk sac tumour) and choriocarcinoma (Andrew & Jules, 2011). 
Up until now, the exact cause of ovarian cancer is still unknown. However, it is 
demonstrated that hereditary ovarian cancer generally occurs within one of two distinct 
genetic backgrounds. The first, hereditary breast and ovarian cancer (HBOC) syndrome, is 
attributable to germline mutations in the BRCA1 or BRCA2 tumour suppressor genes 
(Kuschel et al., 2000; Lee et al., 2000), while the second is associated with hereditary non-
polyposis colorectal cancer (HNPCC), or Lynch Syndrome, which is attributable to a 
germline mutation in one of several genes located within the DNA mismatch repair 
pathway (Russo et al., 2009; Lu et al., 2008). 
Recent evidence supports the notion that the genetic background underlying ovarian 
tumour genesis extends well beyond these familial conditions and that the development of fully 
malignant tumours involves the progressive acquisition of mutations in multiple genes, 
including BRAF, KRAS, PTEN, Her2/neu, c-myc, p16, and p53 (Shih et al., 1998; Pearson et 
al., 1998 Stanley et al., 1995). Although these molecular alterations have been identified in a 
significant fraction of ovarian cancers, none of these mutations are diagnostic of malignancy or 
predictive of tumour behavior over time. Furthermore, the frequency of several of the above 
mutations appears to be highly dependent on the histological subtype of the tumour (Shih et al., 
1998). 
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The lifetime risk of developing ovarian cancer place at 1.39% and the risk factors 
for the development of ovarian cancer includes age of the individual if it is above forty 
(Ness et al., 1999), family history of ovarian, breast, cervical or colon cancer, early age of 
menarche, late menopause (Cramer et al., 2001) and nulliparity (Rodriguez et al., 2001). 
Other than age and genetic background, the risk factor associated with ovarian cancer 
includes the use of hormone replacement therapy or fertility drugs, diet and ethnicity (Folch 
and Soloane, 1957).  
 
1.2.2 Ovarian cancer screening: current trend and obstacles 
 The failure to detect ovarian cancer at an early stage can cause high mortality to the 
ovarian cancer patients. Screening for early detection strategies are believed to have 
potential in improving patient survival (Baker et al., 1994). At present, women who are 
identified as high risk of ovarian cancer need to rely on genetic counseling and screening of 
serum CA 125 and transvaginal sonography (Bast et al., 2007). CA 125 is not a diagnostic 
or prognostic marker but its used have been demonstrated currently in monitoring treatment 
response and disease. 
 Although the detection and monitoring can be done in various ways such as CA 
125, transvaginal sonography (TVS), doppler and morphological indices, each method is 
lacking of the specificity required in general population detection (MacDonald et al., 1998). 
For example, the CA 125 assays showed only 50-60% sensitivity at stage I of the disease 
(Jacobs et al., 1989). In addition, the CA 125 test also showed less sensitive to 
premenopausal women compared to post menopausal (Haaften-Day et al., 2001).  
 A screening strategy that combines the use of tumour measured at specific intervals 
with ultrasound may represent a cost-effective strategy for early detection and may yield 
higher sensitivity and specificity (Jacob et al., 2004; Menon et al., 2001). However, this 
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strategy relies solely on CA 125 which unlikely provides a sufficient sensitivity for early 
stage diseases. Another strategy is to combine a potential biomarker with CA 125 in order 
to determine the risk stratification. Several papers had demonstrated the combination of CA 
125 and Human Epididymal Protein 4 (HE4) had an improved sensitivity and specificity for 
earlier detection of ovarian cancer (Huhtinen et al., 2009; Moore et al., 2009; Moore et al., 
2008). A diagnostic analyser to detect HE4 is now commercially available in the market. 
However, HE4 is also reported to be elevated in all stages of endometrial cancer and its 
sensitivity is more towards early stage of endometrial cancer when compared to CA 125 
(Moore et al., 2008).  
Since prevalence of ovarian cancer in general population is relatively low, any 
proposed strategy must demonstrate a minimum specificity of 99.6% and a sensitivity of 
more than 75% for early stage disease to achieve a positive predictive value of 10% and 
avoid an unacceptable level of false positive results (Jacob et al., 2004; Menon et al., 
2001). Therefore, considering that the ovarian cancer is asymptomatic and the tumours can 
mainly develop from various types of the cells, there is an urgent need to develop additional 
informative biomarker, identification of a novel biomarker or combination of biomarkers 
that can detect small pre-symptomatic ovarian tumours and differentiate malignant from 
benign tumours with high level of sensitivity and specificity. 
 
1.3 Cervical cancer  
Cervical cancer is the second most common malignancy in women worldwide, and 
it remains as a leading cause of cancer-related death for women in developing countries. In 
Malaysia, cervical cancer is the second most common cancer that happens among women 
aged between 30-69 years (Othman, 2003). Cervical cancer mortality rates in Malaysia 
declined from 1985 to 1993 and then increased in 1997 (National Cancer Registry, 2002). 
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According to the latest third report (National Cancer Registry, 2008), a total of 4,057 cases 
of cervical cancer had been reported from 2003 until 2005. The incidence of cervical cancer 
in the Malaysian‟s Chinese is among the highest compared to the other races in the country 
and also the Chinese women in other Asian countries. 
 
1.3.1 Human pappiloma virus and cervical carcinoma 
The cervical cancer cells begin to grow in the normal cells lining of the cervix. 
Human Pappiloma Virus (HPV) is a DNA virus and high risk HPV has been accredited in 
99.7% of invasive cervical cancer (Walboomers et al., 1999). After infection, the cells of 
the cervix gradually develop pre-cancerous changes and then turn into cancer cells. 
However, only certain type of HPV are considered as high-risk types which include type 
16, 18, 31, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82 (Muñoz et al., 2003).  
 Although the increasing scenario of cervical cancer is more likely due to the 
increasing of HPV infection (Adeeb et al., 2007), the actual prevalence of HPV infection 
among Malaysian women is remain unknown since there is no large study on HPV in 
Malaysia. However, large studies on prevalence of HPV infection have been conducted in 
four Asian countries namely India, Vietnam, Korea and Thailand. The study showed that 
the age standardised prevalence for any HPV is 8.7%, with the high-risk types representing 
a large portion of the infected women (5.4%) (Clifford et al., 2005).  
Apart from HPV infection, other factors such as smoking, chlamydial infection, low 
diet intake of fruits and vegetables (Ghosh et al., 2008), consumption of oral contraceptives 
and diethylstilbestrol (Hatch et al., 2001) can cause cervical cancer although their 
contribution is small toward the disease. 
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1.3.2 Cervical cancer vaccine as a primary prevention 
 Since early year of 2009, media publicity on the prevention of cervical cancer has 
been made (http://health.asiaone.com/Health/Women) especially by taking human 
papilloma virus (HPV) vaccine also, known as cervical cancer vaccine (Ault et al., 2007). 
In 2006, a vaccine called Gardasil was used to protect against HPV types 6, 11, 16 and 18 
(The Future II Study Group in 2007). Another vaccine, Cervarix has been approved by the 
Food and Drug Administration in 2009 to be used in the United States to protect women 
against HPV types 16 and 18. Recommendation for HPV vaccination was also published on 
2009 by the Federal Advisory Committee on Immunization Practices (ACIP). 
 Malaysian Ministry of Health had promoted and initiated the HPV vaccination to 
girls with the age of 13 since 2009. However, the issues of cost-effectiveness and long term 
benefits are yet to be answered. There are a few issues that have to be addressed such as the 
duration of protection, the need for booster and efficacy in older women. The efficacy of 
this vaccine program towards Malaysian secondary school students may reduce the risk 
factor of getting the cervical cancer. However, the statistical data revealing the involvement 
of pre-marital sexual intercourse since the age of 12 (Lee et al., 2006) is somewhat 
disturbing. It is not impossible that the issue of when the vaccination among adolescents 
should begin might arise again in the future and the cost-effectiveness as well as efficacy of 
prevention might be questionable.  
 
1.3.3 Cervical cancer screening program: current status 
 Detection of cervical cancer can be made if women undergo regular Papinacalau 
(PAP) smear test (Wright et al., 2007). PAP smear is a medical procedure in which sample 
of cells from a woman‟s cervix covering the end of the uterus that extends into the vagina is 
collected and smeared on a microscope slide. Incidence and mortality due to cervical cancer 
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was significantly reduced in countries with organized PAP smear screening program (Laara 
et al., 1987). 
 According to the National Cervical Cancer Guidelines 2003 and Guidebook in PAP 
smear 2008, all sexuality active women age between 20-65 years shall undergo PAP smear 
screening annually for two consecutive years and if the PAP smear is normal in both 
occasions, the screening test can be continued once every three years. However, a 
community survey done by National Health and Morbidity Survey in 1996 found that the 
coverage of the PAP smear screening program was 26% among the Malaysian woman 
which indicates that awareness regarding PAP smear is relatively low. 
 Several possibilities was associated with what was stoping the Asian  women from 
going to their regular yearly or three yearly PAP smears. Women were not empowered with 
the knowledge they need to seek preventive screening, especially older women since they 
are unlikely to visit family planning clinics (Anon, 1997). Beside that, strong belief in 
traditional medicine, feeling fear and discomfort towards the medical procedures are also 
the reasons why women put the PAP smear screening into denial (Cheah and Looi, 1999). 
 
1.3.4  New technology for cervical cancer screening 
 An atypical squamous cell of undetermined significance (ASC-US) is a major 
limitation during the PAP smear test. New technologies for cervical cancer screening are 
currently developed and one example is by HPV testing using Hybrid Capture 2. The 
analysis was approved by the FDA in 2003 as a primary screening test. This is due to a 
study conducted on 7932 women with the median age of 34 years which had shown 100% 
sensitivity in detecting a histologically proven high grade squamous intraepithelial lesion 
(HGSIL) and higher specificity in women age more than 30 years (Clavel et al., 2001). 
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 Although the study involved a large number of individuals, strategies have to be 
streamlined to capture not only women age more than 30 years but also the reproductive 
age group from 20-30 years. In conjunction to the problems and the issues which is initially 
mentioned, an identification of a protein(s) as a novel molecular marker is such a favorable 
attempt in distinguishing healthy and cervical cancer women which not involved cells as a 
sample that might contribute to the insensitivity screening due to the age factor. 
 
1.4  Cancer staging system  
 Cancer staging is a basic activity in the area of oncology. It is structured to represent 
a major prognostic factor in predicting patients‟ outcome and lending order to the complex 
dynamic behavior of a cancer (Benedet et al., 2006). One of the major purposes of cancer 
staging is to offer a classification of a cancer‟s extent in order to provide a method of 
conveying one‟s clinical experience to other for the comparison of treatment methods 
without ambiguity. 
 Tumour classification is generally conceived so that the clinical and/or pathological 
spread is stratified into 4 stages: Stage I refers to a tumour strictly confined to the organ of 
the origin; Stage II describes disease that has extended locally beyond the site of origin to 
involve adjacent organs or structures; Stage III represents more extensive involvement such 
as wide infiltration reaching neighboring organs and Stage IV represents clearly distant 
metastatic disease (Pecorelli et al., 2006). These four basic stages are then classified into 
sub stages, as a reflection of specific clinical, pathological, or biological prognostic factors 
within a given stage (Bösze et al., 2001). Gospodarowicz et al., in 1998 suggest that these 
certain factors such as the site of origin of the disease, its biology, and the extent of the 
disease at the time of presentation is required in order to optimally manage any malignant 
disease.  
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Over the last 30 years, all changes to the FIGO classification and staging system 
have been extensively discussed by the FIGO Committee on Gynecologic Oncology and 
put forward in agreement with and approved by the Union Against Cancer (UICC) tumour-
node-metastasis classification (TNM) Committee, the American Joint Committee on 
Cancer (AJCC), and the World Health Organization. Tables 1 and 2 provide the current 
FIGO staging classifications published in the Twenty-sixth Volume of the FIGO Annual 
Report (Pecorelli et al., 2006). Over the years, the UICC, AJCC, and FIGO have modified 
their staging systems for gynecological cancers so that all three systems are virtually 
identical (Gospodarowicz et al., 1998).  
Currently, an agreement between the three bodies ensures comparability of staging 
classifications for gynecologic malignancies and their representatives meet annually. The 
interaction among these bodies has led to the creation of uniform information shared within 
the scientific community (Pettersson et al., 2001) thereby promoting continuous uniformity 
between all bodies. Further and joint efforts are constantly made to unify the FIGO and 
TNM classifications. 
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Table 1 Carcinoma of the ovary: FIGO nomenclature (Rio de Jeneiro 1988) 
Stage I 
 
Growth limited to the ovaries. 
Stage Ia: Growth limited to one ovary: no ascites present containing 
malignant cells. No tumour on the external surface; capsule intact. 
Stage Ib: Growth limited to both ovaries: no ascites present containing 
malignant cells. No tumour on the external surfaces; capsules intact. 
Stage Ic
a
: Tumour either Stage Ia or Ib, but with tumour on surface of 
one or both ovaries, or with capsule ruptured, or with ascites present 
containing malignant cells, or with positive peritoneal washings. 
Stage II 
 
Growth involving one or both ovaries with pelvic extension 
Stage IIa: Extension and/or metastases to the uterus and/or tubes. 
Stage IIb: Extension to other pelvic tissues. 
Stage IIc
a
: Tumour either Stage IIa or IIb, but with tumour on surface of 
one or both ovaries, or with capsule(s) ruptured, or with ascites present 
containing malignant cells, or with positive peritoneal washing. 
Stage III 
 
 
Tumour involving one or both ovaries with histologically-confirmed 
peritoneal implants outside the pelvis and/or positive retroperitoneal or 
ingual nodes. Superficial liver metastases equal Stage III. Tumour is 
limited to the true pelvis, but with histologically-proven malignant 
extension to small bowel or omentum. 
Stage IIIa: Tumour grossly limited to the true pelvis, with negative 
nodes, but with histologically-confirmed microscopic seeding of 
abdominal peritoneal surfaces, or histologic proven extension to small 
bowel or mesentry. 
Stage IIIb: Tumour of one or both ovaries with histologically-
confirmed implants, peritoneal metastasis of abdominal peritoneal 
surfaces, none exceeding 2 cm in diameter: nodes are negative.   
Stage IIIc: Peritoneal metastasis beyond the pelvis >2cm in diameter 
and/or positive retroperitoneal or ingual nodes. 
Stage IV 
 
Growth involving one or both ovaries with distant metastases. If pleural 
effusion is present, there must be positive cytology to allot a case to 
Stage IV. Parenchymal liver metastasis equals Stage IV. 
a
 In order to evaluate the impact on prognosis of the different criteria for allotting cases to 
Stage Ic or IIc, it would be a value to know if rupture of the capsule was spontaneous, or 
caused by the surgeon; and if the source of malignant cells detected peritoneal washings, or 
ascites. 
 
Reprinted from: Heintz APM, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, 
Creasman WT, et al. Carcinoma of the ovary. Int J Gynecol Obstet 2006; 95 (Suppl 
1):S163. 
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Table 2:  Carcinoma of the cervix uteri: FIGO nomenclature (Montreal, 1994) 
Stage 0  
Carcinoma in situ, cervical intraepithelial neoplasis Grade III. 
Stage I  
The carcinoma is strictly confined to the 
cervix (extension to the corpus would be 
disregarded). 
 
Stage 1a: Invasive carcinoma which can be 
diagnosed only by microscopy. All 
macroscopically visible lesions – even with 
superficial invasion – are allotted to Stage Ib 
carcinomas. Invasion is limited to a 
measured stromal invasion with a maximal 
depth of 5.0 mm and a horizontal extension 
of not >7.00 mm. Depth of invasion should 
not be >5.0 mm taken from the base of the 
epithelium of the original tissue should not 
change the stage allotment. 
Stage Ia1: Measured stromal invasion of 
not >3.0 mm in depth and extension of not 
>7.0 mm. 
 
 
Stage Ia2: Measured stromal invasion of 
>3.0 mm and not >5.0 mm with an 
extension of not >7.0 mm. 
 
Stage Ib: Clinically visible lesions limited to 
the cervix uteri or preclinical cancers greater 
than Stage Ia 
Stage Ib1: Clinically visible lesions not >4.0 
cm. 
Stage Ib2: Clinically visible lesions >4.0 
cm. 
Stage II 
Cervical carcinoma invades beyond uterus, 
but not to the pelvic wall or to the lower 
third of vagina. 
 
Stage IIa: No obvious parametrial 
involvement 
Stage IIb: Obvious parametrial involvement. 
Stage III  
The carcinoma has extended to the pelvic 
wall. On rectal examination, there is no 
cancer-free space between the tumour and 
the pelvic wall. The tumour involves the 
lower third of the vagina. All cases with 
hydronephrosis or nonfunctioning kidney 
are included, unless they are known to be 
due to other cause. 
Stage IIIa: Tumour involves lower third of 
the vagina, with no extension to the pelvic 
wall. 
Stage IIIb: Extension to the pelvic wall 
and/or hydronephrosis or nonfunctioning 
kidney. 
Stage IV  
The carcinoma has extended beyond the true 
pelvis or has involved (biopsy proven) the 
mucosa of the bladder or rectum. A bullous 
edema, as such, does not permit a case to be 
allotted to Stage IV. 
Stage IVa: Spread of the growth to adjacent 
organs. 
Stage IVb: Spread to distant organs like the 
lungs.  
 
Reprinted from: Quinn MA, Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman 
WT, et al. Carcinoma of the cervix uteri. Int J Gynecol Obstet 2006;95 (Suppl 1):S43. 
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1.5 Urinary proteins 
Urine has been used over the centuries mainly for the study and monitoring of renal 
physiology and pathology (Papale et al., 2007). For example, the presence of albumin in the 
urine has been measured as an indicator for renal disease whereas human chronic 
gonadotropin which is present in the urine is used in the pregnancy test kit to detect 
pregnancy of women. Recently, urine was extensively studied as a potential source of 
biomarkers due to the non-invasive nature of getting the sample from the patient (Pieper et 
al., 2004; Spahr et al., 2001). Approximately up to 150 mg of proteins and peptides are 
excreted in urine per day from individual who does not have any kidney problem. 
The proteins from the urine were usually originated from glomerular filtration of 
blood plasma, cell apoptosis (Pavenstadt et al., 2003), secretion of exosomes by epithelial 
cells and proteolytic cleavage of cell surface glycosylphosphatidylinositol-linked proteins 
(GPI). Around 50% of these proteins are derived from glomerular filtration (Zhou et al., 
2006). Low molecular weight proteins which are less than 10 kDa can pass freely through 
glomerular barriers and almost none of high molecular weight proteins or only a fraction of 
proteins with middle molecular weight reach renal tubules (Christensen and Birn, 2001). 
However, proteins that are abundant in the blood plasma such as albumin and various 
globulins can pass through the glomerular filter in substantial amounts. 
 
1.5.1 Application of urine in diseased detection 
A change in a given soluble protein concentration in the blood plasma, or a change 
in the function of the glomerular filter or an alteration in the proximal tubule scavenging 
system can result to a change in its amount in the final urine. Changes in the urinary 
proteome may therefore be used to detect not only abnormalities within the kidney and the 
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urogenital tract but also systemic disease associated with small circulating protein and 
peptide markers that can pass through the glomerular filter (Jonathan and Topham, 2007). 
In the search for new protein biomarker candidates with clinical diagnostic value, 
substantial progress was made in the proteomic analysis of serum samples of patients with 
different cancers (Pang et al., 2010; Cordero et al., 2008; Maurya et al., 2007). In contrast, 
fewer studies have been carried out on the urine samples of cancer patients. However, the 
identification of more than 1500 proteins in the urine of healthy donors which had being 
performed using advanced mass spectrometry techniques (Adachi et al., 2006) gave an 
advantage to the new researches in term of streaming down the analytical strategy and 
comparison purposes. Investigation using the SELDI-TOF-MS technique done on urine of 
patients with ovarian carcinoma which is restricted to the low molecular weight peptide 
analysis (Ye et al., 2006) proves that wider coverage could be done in order not to miss out 
any potential biomarker. Thus, making a proteomic as a favorite approach among the 
researchers to understand diseases and this perhaps could lead to the development of more 
effective treatments. 
 
1.5.1.1 Proteomic and urinary tract disease 
Interstitial cystitis (IC), an example of urinary track disease, is recently being 
studied using proteomic technique. IC is a chronic disease that consists of urinary urgency, 
frequency and bladder pain (Curhan et al., 1999). The urge of the study is basically due to 
often delay in the treatment of IC since there is no known cause or reliable method of 
diagnosis. Investigation using proteomic approached manage to identify a candidate 
biomarker for the diagnosis of IC where the increased of anti proliferative factor (APF) 
activity in the bladders of patients with IC were demonstrated (Zhang et al., 2001). Another 
attempt to understand the disease was done by correlating the patient quality-of-life scores 
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and IC symptom scores in order to determine whether there is a linear association between 
quantitative biomarker analysis and standardised measures of activities of daily living, 
symptom severity, and pain (Canter et al., 2008). Although this study had declared the 
exclusion of APF protein in their study, they had shown a promising result by 
demonstrating the correlation between IC severity with the decrease in Tamm-Horsfall 
protein (THP) and kininogen in the urine of the patients. 
 
1.5.1.2 Proteomic and cancer  
 Colorectal cancer is the second most common cause of cancer related to death in a 
developed country but early diagnosis often leads to a complete cure (Burt et al., 2010). 
Many cases of colon cancer have no symptom; however the blood in the stool (Lieberman 
et al., 2009) and abdominal pain and tenderness in the lower abdomen (Millham et al., 
2010) may indicate colon cancer. Foecal occult blood test (FOBT) is used to screen the 
disease and showed a significant reduction in mortality (Hewitson et al., 2007). It is a test 
to check stool for blood that can only be seen with a microscope. However, this test cannot 
tell whether the blood is from colon or from other parts of the digestive tract such as 
stomach.  If this test is positive, a procedure to look inside the rectum and colon for polyps, 
abnormal areas called colonoscopy is needed to find the cause of bleeding. 
Another stool-based approach is stool DNA test (sDNA). Instead of looking for 
blood in the stool, this test looks for abnormal DNA from cancer or polyp cells. Although 
the test appears effective and cost-effective, but the test is poorer compared to other 
strategies such as FOBT and colonoscopy (Song et al., 2004). A protein biomarker namely 
carcinoembryonic antigen (CEA), is a tumour marker used to trace cancer in 
gastrointestinal tract. However, it is not an effective screening test due to the low sensitivity 
in patients at early stage of the disease (Hurst et al., 2007). 
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 Up until now, no blood or stool biomarkers with both high sensitivity and 
specificity for potentially curable early stage disease have been validated for clinical use. A 
proteomic approaches have shown that in principle, they are capable of uncovering 
biomarkers with high sensitivity and specificity. For example, Ward et al., (2006) manage 
to find a panel of biomarker for colon cancer with greater sensitivity and specificity when 
compared to CEA In their study, although there is a considerable overlapping between 
different approach of proteomic technique such as SELDI and MALDI data, all the 
profiling method detect unique peaks with high sensitivity. Ward et al., (2008) also 
successfully identified hepcidin-20, β2-microglobulin and 18 residue fragment of the α-
subunit fibrinogen in the urine which could be associated with colorectal cancer.  
 
1.5.1.3 Proteomic and animal disease 
 Recent studies also demonstrate that the use of urine for the identification of 
disease-induced biomarkers is not only being applied in human urinary proteins but also in 
animal. Bovine Spongiform Encephalopathy (BSE) and other Transmissible 
Encephalopathy (TSE) diseases are uniformly fatal degenerative syndromes of the central 
nervous system (CNS) that occurred in cattle (Smith et al., 2003). This disease is 
untreatable. A new human variant of Creutzfeldt-Jakob Disease (vCJD) is thought to have 
been caused by  dietary exposure to BSE infected cattle, thus led to profound changes in the 
production and trade of the agricultural goods (Peden et al., 2004). 
 The rapid test currently approved for BSE monitoring in slaughtered cattle are all 
based on the detection of the disease related isoform of the prion protein, PrP
d, 
in brain 
tissue and therefore are only suitable for post-mortem diagnosis. In order to assess the 
health of breeding stock for export purposes where post-mortem testing is not an option, 
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there is a demand for ante-mortem test based on matrix or body fluid that would permit 
easy access and repeated sampling. 
 A study of 2-DE and mass spectrometry analyses were used to identify proteins 
exhibiting differential abundance in the urine of BSE infected cattle and age matched 
controls of the disease (Sharon et al., 2008). This study suggested that in principle, it is 
possible to identify biomarkers in urine. Moreover, the biomarkers found as 
immunoglobulin gamma-2 chain C region, cystatin, cathelicidin, uroguanylin and clusterin 
in this study are useful in the diagnosis, prognosis and monitoring of disease progression of 
transmissible spongiform encephalopathy diseases. 
In conclusion, to date, proteomic experiments that have been conducted on urine 
were not confined to patients suffering from diseases of the genitourinary system 
(Buhimschi et al., 2004) but also others such as mentioned above, it has been carried out on 
those with atherosclerosis (Von-Zur-Muhlen et al., 2009), sleep disorder (Gozal et. al., 
2009), cancers of the bladder (Kreunin et al., 2007), pancreas (Weeks et al., 2008; Kojima 
et al., 2008) and lung (Tantipaiboonwong et al., 2005). Therefore, it is not impossible to 
find a biomarker in urine of the patients with diseases such as ovarian carcinoma and 
cervical cancer too.    
 
1.5.2 Proteomic methods used in this study 
In this present study, 2-DE coupled with mass spectrometry identification and 
SELDI-TOF were adopted for the screening of diseased and control individuals. Due to the 
different approach on protein detection, these two techniques complement each other where 
wider range of proteins could be screened for potential biomarker. 
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1.5.2.1  Two dimensional gel electrophoresis coupled with MALDI-TOF-MS 
 The 2-DE method was preferred in this study due to the high resolution it gives. 
More importantly, individual protein spots could be visualized, which was not able to be 
done by other proteomic approach. It is also applicable in the studies requiring the 
quantitative analysis in comparing the proteome between different samples (Stein & 
Zvelebil, 2002).  This technique separate complex protein mixtures based on two discrete 
steps. The first-dimension step is the isoelectric focusing (IEF) which separates proteins 
according to their isoelectric points (pI) and the second dimension step is the SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) which separates proteins according to 
their molecular weight. To identify the resolved protein in 2-DE gel, the protein spots can 
be excised, digested and subjected to mass spectrometry. 
Mass spectrometry is an analytical technique that measures the mass of molecules 
based upon the motion of a charged particle in an electric or magnetic field. The data 
obtained are then exported in a format to the database search program, Mascot (Matrix 
Science Ltd, London, UK). The data was searched against „All entries‟ in the SwissProt 
database. High scores in the database search indicated a likely match and confirmed by 
operator inspection. 
 
1.5.2.2  Surface enhanced laser desorption/ionization time of flight-mass spectrometry 
(SELDI-TOF-MS) 
Unlike 2-DE where the protein could be visualised and identified, SELDI-TOF will 
only gives the profile of protein samples based on the target chip used. Comparison 
between samples still can be done based on the profile obtained. SELDI-TOF technique is 
preferred because of its reproducibility and its capacity to permit rapid comprehensive 
large-scale analysis of individual proteins within complex protein mixtures. With the 
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reduction in sample complexity, there is an improved ability to detect lower abundance 
proteins (Lin et al., 2004). SELDI-TOF allows protein profiling from a variety of complex 
biological materials such as serum, blood, plasma, tissue, urine, saliva, cell lysis products 
with limited sample preparation. Complex sample analysis, however, involved 
sophisticated approaches including digestion and labelling of the target proteins (Ferguson 
et al., 2003). In contrast, the label-free quantification of native proteins is an inherent part 
of the SELDI-TOF process and does not require any additional preparation or labelling. 
In the SELDI-TOF method, protein solutions are applied to the spots of ProteinChip 
arrays, which have been derivative with planar chromatographic chemistries. The proteins 
actively interact with the chromatographic array surface, and become sequestered according 
to their surface interaction potential as well as separated from salts and other sample 
contaminants by subsequent on-spot washing with appropriate buffer solutions. 
Furthermore, protein interaction studies or enzymatic reactions may be carried out directly 
on-spot under physiological conditions. The chromatographic surfaces provide a very good 
support for the crystallization of matrix and target proteins, resulting in the formation of a 
homogenous layer on the spot, thereby delivering an ideal crystalline surface for the 
subsequent analysis. 
There are several protein chips array available in the market with different purpose 
of analysis. The protein chips are such as CM10, a weak cation exchange chip that capture 
molecules that have positive surface charges; Q10, a strong anion exchange chip that 
capture molecules that have negative surface charges; IMAC 30, an immobilised metal 
affinity that capture molecules which bind polyvalent metal ions such as nickel, copper, 
zinc, iron and gallium; H50, a hydrophobic protein chip array that capture large proteins 
through hydrophobic or reverse phase interaction; and NP20, a normal phase protein chip 
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that also known as a general protein binding surface. It is recommended for hydrophilic 
proteins.    
The spectrums obtained from the SELDI-TOF are further analysed with 
ChipergenExpress Data Manager and Biomarker Pattern Software™ (BPS). 
ChiphergenExpress Data Manager is an application within ProteinChip Biomarker System 
used to generate peak cluster and export these clusters into a file for analysis in Biomarker 
Patterns
TM 
Software (BPS). BPS is a single procedure that can be used to analyse either 
categorical (classification) or continuous (regression) data with the implementation of 
CART (Classification and Regression Trees). A defining feature of CART is that it 
presents its results in the form of decision trees. This decision trees will gives potential 
protein peaks that can be determined as a potential biomarker/s. 
 
1.6 Aim of the investigation 
The aim of this study was to screen urine from patients with ovarian cancer and cervical 
cancer for a potential biomarker(s). This was done by achieving the following objectives: 
a. To develop 2-DE profile of urinary proteins from control and patients with ovarian 
carcinoma and cervical patients. 
b. To compare 2-DE profile of urinary proteins from control and patients with ovarian 
carcinoma and cervical patients using Image Master 2D Paltinum software. 
c. To identify aberrantly expressed protein using MALDI-TOF-MS/MS.  
d. To verify the identified protein using Western Blotting technique. 
e. To screen the low molecular weight proteins using SELDI-TOF-MS. 
f. To analyse spectrum obtained from SELDI-TOF-MS with ChipergenExpress Data 
Manager and Biomarker Pattern Software™ (BPS) for potential biomarker(s). 
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SECTION A: MATERIALS 
2.1 Urine collections 
 Urine samples were collected from patients which were newly confirmed with 
stages II and III ovarian carcinoma (n = 11) and cervical cancer (n = 11), prior to 
chemotherapy treatment, at the University of Malaya Medical Centre (UMMC), Kuala 
Lumpur.  Control urine samples were collected randomly from age-matched cancer 
negative women (n = 15).  Samples obtained were with consent and approval granted by 
the ethical committee of UMMC in accordance to the ICH GCP guideline and the 
Declaration of Helsinki.  The subjects were of different ethnic background (Malay, Chinese 
and Indian). 
                                                                                                                                                                                                                                                                                                                     
2.2 General material 
The materials used in this study and their respective suppliers are listed below. 
2.2.1 Chemicals and reagents 
 All chemicals were both analytical grade and proteomic grade and were purchased 
from Sigma Aldrich Company, St. Louis, United States of America (USA) with the 
exception of the following: 
a) Amersham Pharmacia Biotech, Uppsala, Sweden 
TEMED (N, N, N‟,N‟-Tetrametyhlenediamine) 
b) Merck, Darmstadt, Germany 
Glycine and Urea  
c) Bio-Rad, Hercules, USA 
Bis N, N‟,-methylene-bis-acrylamide and Sodium dodecyl sulphate (SDS) 
d) Bio-Rad Laboratories, Richmond, USA 
 Ammonium persulphate 
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e) Merck, Darmstadt, Germany 
Acetic acid, Ammonium sulphate, Sodium chloride 
f) Pierce Biotechnology, Rockford, USA 
 Pierce® BCA Protein Assay Kit 
g) Thermo Scientific Pierce Protein Research Products, Rockford, USA 
SnakeSkin Dialysis Tubing, 10K MWCO 
h) Promega, Wisconsin, USA 
Trypsin Gold 
 
2.2.2 Two-Dimensional gel electrophoresis 
 IEF immobiline dry strips (pH 3-10), pharmalyte 3-10 and drystrip cover fluid were 
supplied by GE Healthcare, Uppsala, Sweden. 
 
2.2.3 Antibodies 
a) Abcam, Cambridge, United Kingdom 
 Anti-human CD59 
b) Abnova, Jhongli, Taiwan 
 Anti-human kininogen-1 
c) Sigma Aldrich Company, St. Louis, USA 
Anti-albumin, Anti-rabbit IgG (whole molecule)-Peroxidase, Anti-mouse IgG (Fc 
Specific)-Peroxidase 
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SECTION B: METHODS 
2.3 Urine samples 
2.3.1 Pre-treatment of urine samples 
 Sodium azide was immediately added to the urine upon collection to a final 
concentration of 20 mM.  The samples were centrifuged at 10,000 rpm at 4
o
C and the 
supernatant was collected and dialysed using 10-kDa cutoff dialysis tubing (Pierce, 
Rockford, USA) against distilled water.  The urine proteins were aliquot, freeze-dried and 
kept at –20ºC.  Protein content was determined using the Pierce BCA protein assay kit. 
 
2.3.2 Determination of urine sample concentration 
 The protein concentration of urine samples was determined using the BCA 
(Biochichoninic acid) protein assay where the amount of protein in the urine sample was 
estimated from a constructed standard curve. This is important in order to standardize the 
amount of protein to be analyzed with two-dimensional gel electrophoresis and SELDI-
TOF-MS. 
 
2.3.2.1 Preparation of the BCA Working Reagent (WR) 
 The following formula was used to determine the total volume of WR required: 
(# standards + # samples) × (# replicates) × (volume of WR per sample) = total volume WR 
required. 
 The WR was prepared by mixing 50 parts of BCA Reagent A with 1 part of BCA 
Reagent B (50:1, Reagent A: B). When Reagent B was first added to Reagent A, turbidity 
was observed which quickly disappeared upon mixing to yield a clear, green WR. The WR 
was stored at room temperature (RT) and stable for several days when stored in a closed 
container. Nine vials labeled with A to I was prepared to perform different protein 
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concentration.  To prepare the standard curve, the stock with the concentration of 2000 
μg/ml BSA was diluted as follow: 
Dilution Scheme for Standard Microplate Procedure 
 (Working Range = 20-2000 μg/ml)  
Vial Volume of Diluent 
(μl) 
Volume and Source 
of BSA 
Final BSA 
Concentration 
(μg/ml) 
A 0 300 μl of stock 2000 
B 125 375 μl of stock 1500 
C 325 325 μl of stock 1000 
D 175 175 μl of vial B 
dilution 
750 
E 325 325 μl of vial C 
dilution 
500 
F 325 325 μl of vial E 
dilution 
250 
G 325 325 μl of vial F 
dilution 
125 
H 400 100 μl of vial G 
dilution 
25 
I 400 0 0 (Blank) 
 
2.3.2.2 Protein concentration measurement by microplate procedure 
 The pellete of freeze dried urine sample was redissolved with 1 ml deionized water. 
Twenty five µl of each standard and urine samples were pipetted into a microplate well 
(working range = 20-2000 μg/ml). Two hundred µl of the WR was added to each well and 
the plate was shaked thoroughly on a plate shaker for 30 seconds. The plate was covered 
and incubated at 37ºC for 30 minutes. The plate was cooled down to RT and the absorbance 
was measured at 562 nm on a plate reader. A graph of absorbance against protein 
concentration was plotted and the concentration of urinary protein was determined based on 
graph (Figure 3). 
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Figure 3: Standard curve of protein concentration 
 The standard curve was constructed based on BSA solution with concentrations 
ranging from 20-2000 µg/ml using Pierce BCA protein assay kit. The absorbance was read 
at 562 nm. Protein concentration in the urine samples was estimated based on the standard 
curve.  
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2.4 Two-dimensional gel electrophoresis (2DE) 
2.4.1 First dimension electrophoresis 
2.4.1.1 Stock solution 
Rehydration solution with pharmalyte [8 M urea, 0.5% (v/v) Pharmalyte 3-10, 0.5% (v/v) 
NP-40] 
  Urea      12.00 g 
  Pharmalyte 3-10     0.50 ml 
  NP-40      0.13 ml 
  A few grains of Orange G 
The solution was made up to 25 ml by addition of deionized water and was stored at      
-20ºC until used. Prior to use, 7 mg of DTT was added to every 2.5 ml of rehydration 
solution. 
 
2.4.1.2 Rehydration of immobiline dry strip 
  First, 300 µg of freeze-dried of urinary protein was dissolved in 200 l rehydration 
solution. The sample was centrifuged at 5000 rpm for 15 minutes before it was pipetted into 
the reservoir slot of the immobiline drystrip reswelling tray (GE Healthcare, Uppsala, 
Sweden) which had been leveled by turning its leveling feet. After loading the sample 
mixture into the reswelling tray, 11 cm immobilized pH gradient (IPG) drystrips with the 
pH gradient of 3-10 L (linear) was positioned with the gel side down onto the solution. 
Subsequently, IPG drystrip cover fluid was pipetted onto the IPG strip until the entire strip 
was covered to minimize evaporation and to prevent urea crystallization. The strip was 
allowed to rehydrate for 18 hours at room temperature to ensure complete uptake of sample 
by IPG strip. 
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2.4.1.3 First dimension run 
 The temperature of the Multiphor™ II Electrophoresis Unit (GE Healthcare, 
Uppsala, Sweden) was set at 20ºC using a thermostatic circulator Eyela CA-1310 (Tokyo 
Rikakikai Co., Tokyo, Japan). Nine ml of dry strip cover fluid was pipetted onto the center 
of the cooling plate. The immobilline drystrip tray was positioned on the cooling plate and 
9 ml of dry strip cover fluid was poured on the tray. Then, the drystrip aligner was placed 
inside the tray, on top of the dry strip cover fluid. IPG strips were positioned inside the 
grooves of the aligner with the acidic end facing the top of the tray. Moistened electrode 
strips were placed across the cathodic and anodic ends of the aligned IPG strips. Next, each 
IPG strip was overlaid with dry strip cover fluid to ensure good thermal contact. The 
electrodes in the Immobiline Dry Strip tray were ensured to be connected before placing the 
lid to the EPS 3501 XL (GE Healthcare, Uppsala, Sweden) power supply. The first 
dimension isoelectric focusing running conditions was as follow: 
 
Phase Voltage (V) Miliampere (mA) Watt (W) Volt-hour (Vh) 
1 300 2 5 1 
2 3500 2 5 2900 
3 3500 2 5 9100 
 
 Once the first dimension electrophoresis was completed, the focused strips were either 
used immediately for the second-dimension separation or were kept individually in screw-
cap tubes at -80ºC. The strips that have been kept were used within 2 weeks. 
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2.4.2 Second-Dimension Electrophoresis 
2.4.2.1 Stock solutions 
 
Monomer stock solution (Solution A) [30% acrylamide, 0.8% N,N‟-
methylenebisacrylamide] 
 Acrylamide    60.0 g 
 N,N‟-methylenebisacrylamide  1.6 g 
The solution was made up to 200 ml with MiliQ water. It was filtered and kept in a dark 
bottle.  
 
4× Resolving gel buffer (Solution B) [1.5 M Tris-HCl, pH 8.8] 
 
 Tris base     181.7 g 
The Tris base was dissolved with 750 ml MiliQ water. After adjusting the pH to 8.8 with 
HCl, the solution was made up to 1 L with MiliQ water. 
 
10% SDS (Solution C) 
 SDS     5 g 
The solution was made up to 50 ml with MiliQ water. 
 
10% Ammonium persulfate (Solution D) 
 Ammonium persulfate   0.1 g 
The solution was made up to 1 ml with MiliQ water and prepared just prior to use. 
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SDS equilibration buffer [50 mM Tris-HCl, pH 8.8, 6 M urea, 30% glycerol, 2% SDS] 
  1.5 M Tris-HCl, pH 8.8   10.00 ml 
  87% (v/v)Glycerol   69.00 ml 
  Urea     72.07 g 
  SDS       4.00 g 
The solution was made up to 200 ml with deionized water. The solution was stored at 
 -20˚C. 
 
5% Agarose sealing solution 
  Agarose     0.50 g 
  SDS electrophoresis buffer  100.00 ml 
The mixture was swirled to disperse and heated in a microwave oven until the agarose 
was completely dissolved. 
 
SDS electrophoresis buffer [25 mM Tris-HCl, pH 8.3, 192 mM glycine, 0.1% SDS] 
  Tris-base     15.15 g 
  Glycine      72.00 g 
  SDS     5.00 g   
The solution was made up to 5 L with deionized water. 
 
2.4.2.2 Preparation of 12.5% homogenous SDS-PAGE gel 
  The Hoefer SE 600 (GE Healthcare, Uppsala, Sweden) was used for second-
dimension electrophoresis. This electrophoresis unit consists of gel casting stand and glass 
plates to be assembled like a club sandwich. Four gels were run at one time using the club 
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sandwich divider. A vertical 12.5% gel was prepared by mixing the stock solution 
according to the following recipe: 
Stock Solution Volume of stock solution  
Solution A (ml) 41.70 
Solution B (ml) 25.00 
Solution C (ml) 1.00 
Top up with double distilled water (ml) 31.80 
*Solution D (l) 500.00 
*TEMED (l) 33.00 
Total volume (ml) 100.00 
*TEMED need to be added immediately once solution D was added into the solution. 
 After mixing the solutions, the gel solution was poured slowly between the gaps of 
sandwich-assembled glass plates. It was then overlaid with distilled water and was allowed 
to polymerize for a minimum of 1 hour. 
 
2.4.2.3 Equilibration of IPG strips 
  Equilibration of IPG strip was performed in two discrete steps. First, the strip was 
equilibrated with 5 ml SDS equilibration buffer containing 50 mg DTT for 15 minutes with 
gentle shake on a shaker. The solution was then replaced with the SDS equilibration buffer 
containing 4.5% (w/v) iodoacetamide and a few grains of Bromophenol Blue. The strip was 
then shaken for another 15 minutes. The IPG strip was removed from the tube and rinsed 
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with SDS electrophoresis buffer before it was placed on the casted 12.5% homogenous 
SDS-PAGE gel. The strip was sealed with 0.5% agarose sealing solution. 
 
2.4.2.4 Second-dimension run 
  The temperature of the SDS electrophoresis buffer in the 2-DE tank (Hoefer SE 
600, Uppsala, Sweden) was maintained at 16ºC using a thermostatic circulator. 
Electrophoresis was performed at a constant current in two steps as follow: 
Phase Voltage (V) Milliampere (mA) Watt (W) Time (Hour) 
1 50 25 1.4 0.5 
2 600 25 15 2 
 
  The stated values for miliampere and watt were per gel. Electrophoresis was 
stopped once the dye front was approximately 1 cm from the bottom of the gel. Then, the 
gel was removed from its cassette and the protein spots were visualized by silver staining.  
 
2.5 Silver staining 
  The silver staining method was conducted according to the method introduced by 
Heukeshoven and Dernick (1988), with some modifications. A hundred and twenty five ml 
of solution was used per gel. 
 
2.5.1 Stock solutions 
Fixing solution [40% (v/v) ethanol and 10% (v/v) acetic acid] 
  Methanol     400.00 ml 
  Acetic acid    100.00 ml 
 The solution was made up to 1 L with double distilled water. 
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Sentizing solution [30% (v/v) ethanol, 0.13% (v/v) glutaryldehyde, 0.5 M sodium        
acetate, 8 mM sodium thiosulphate] 
 Ethanol     75.00 ml 
 50% (w/v) glutaryldehyde  0.75 ml 
 Sodium acetate trihydrate   17.00 g 
 Sodium thiosulphate pentahydrate 0.50 g 
 The solution was made up to 250 ml with double distilled water. 
 
Silver solution [5.9 mM silver nitrate, 0.02% (v/v) formaldehyde] 
  Silver nitrate    0.25 g 
  35% (v/v) Formaldehyde   50.00 l* 
 The solution was made up to 250 ml with double distilled water. 
 
Developing solution [0.24 M sodium carbonate, 0.02% (v/v) formaldehyde] 
  Sodium carbonate    6.25 g 
  35% (v/v) Formaldehyde   50.00 l* 
 The solution was made up to 250 ml with double distilled water. 
 
Stop solution [40 mM EDTA-Na2.2H2O]   
  EDTA-Na2.2H2O    3.65 g 
 The solution was made up to 250 ml with double distilled water. 
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Preserving solution [10% (v/v) glycerol] 
  Glycerol     25.00 ml  
 The solution was made up to 250 ml with double distilled water. 
(*) All these components were added immediately before use. 
 
2.5.2 Silver staining protocol 
 All incubation steps of silver staining were carried out with gentle shaking on a 
shaker. After completion of the electrophoresis run, the gel was immersed immediately in 
the fixing solution and left for at least 30 minutes to allow SDS to diffuse out and to 
precipitate the proteins. Fixing solution was then replaced with the sensitising solution and 
the gel was incubated overnight. After that, the gel was washed three times with distilled 
water for 5 minutes. Then, the gel was incubated in silver solution for 40 minutes. The gel 
was then rinsed with approximately 50 ml of developing solution and left to develop in 
fresh developing solution. Once protein spots were developed on the gel, the developing 
solution was removed and the colour development was stopped by adding stop solution. 
The gel was left in the stop solution and shaken for 10 minutes. The gel was washed again 
with distilled water for 5 minutes with one change of water.  
 
2.5.3 Gel Scanning and image analysis  
 The silver stained gel was scanned using Image Scanner III (GE Healthcare, Uppsala, 
Sweden). Urinary protein profiles of healthy control women and patients with ovarian 
cancer and cervical cancer were analyzed for abnormally expressed proteins using Image 
Master 2D Platinum Software 7.0 (GE Healthcare, Uppsala, Sweden). The levels of 
proteins in each sample were calculated as a percentage of volume contribution (% vol). In 
order to eliminate the possible variations due to staining, the volume of contribution refers 
  /MATERIALS AND METHODS/ 
37 
 
 
to the volume percentage of a protein taken against the total spot volume of all the proteins. 
The Student‟s t-test was used to analyze the significance of difference between control and 
each disease. 
 
2.6 MALDI-TOF mass spectrometry analysis for protein identification 
 
 To identify the proteins of interest that were differentially expressed, the spots were 
subjected to MALDI-TOF mass spectrometry for protein identification. Proteins separated 
by gel electrophoresis can be visualized using a number of staining methods, however only 
some of these are compatible with protein digestion and mass spectrometric analysis. 
Therefore, preparation of prep-gel was required and the gel need to be stained with vorum 
silver stained according to the method of Shevchenko et al. (1996) for the protein 
identification analysis of abnormally expressed urine protein found in ovarian and cervical 
cancer patients. 
 
2.6.1 Vorum silver staining 
 Two hundred ml of solution was used per gel. This staining method was different 
from method described previously in Section 2.5 mainly due to omittion of glutaryldehyde.  
2.6.1.1 Stock solutions 
Fixing solution [50% (v/v) methanol, 12% (v/v) acetic acid and 0.048% (v/v) 
formaldehyde] 
  Methanol        200.00 ml 
  Acetic acid       48.00 ml 
  35% (v/v) Formaldehyde      190.00 μl 
 The solution was made up to 400 ml with MiliQ water. 
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Wash solution [35% ethanol] 
        Ethanol                420.00 ml 
 The solution was made up to 1.2 L with MiliQ water. 
 
Sensitizing solution [1 mM sodium thiosulphate] 
 Sodium thiosulphate                   0.10 g 
 The solution was made up to 400 ml with MiliQ water. 
 
Silver solution [0.02% (w/v) silver nitrate, 0.076% (v/v) formaldehyde] 
  Silver nitrate        0.80 g 
  35% (v/v) Formaldehyde       288.00 μl 
 The solution was made up to 400 ml MiliQ water. 
 
Developing solution [6% (w/v) sodium carbonate, 0.0004% (v/v) sodium thiosulphate, 0.05 
% (v/v) formaldehyde] 
  Sodium carbonate        48.00 g 
  Sensitizing solution        16.00 ml 
  35% (v/v) Formaldehyde                 378.00 l 
 The solution was made up to 800 ml with MiliQ water. 
 
Stop solution  [50% (v/v) methanol, 12% (v/v) acetic acid] 
  Methanol      200.00 ml 
        Acetic acid      48.00 ml 
 The solution was made up to 400 ml with MiliQ water. 
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Preserving solution [1% (v/v) acetic acid] 
   Acetic acid      10.00 ml  
 The solution was made up to 1 L with MiliQ water. 
 
2.6.1.2 Vorum Silver Staining protocol 
All incubation steps of silver staining were carried out with gentle shaking on a 
shaker. After completion of the electrophoresis run, the gel was immersed immediately in 
the fixing solution and left for at least 2 hours to allow SDS to diffuse out and to precipitate 
the proteins. Following that, the gel was washed three times with washing solution for 20 
minutes.  Washing solution was then replaced with the sensitizing solution and the gel was 
incubated for 2 to 3 minutes. The gel was then rinsed three times with MiliQ water for 5 
minutes. Then, the gel was soaked in silver solution for 20 minutes and again rinsed three 
times with MiliQ water for 5 minutes. The gel was then soaked in developing solution and 
left to develop within 3 to 5 minutes. Once protein spots or bands were developed on the 
gel, developing solution was removed and the colour development was stopped by adding 
stop solution. The gel was left in the stop solution and shaken for 5 minutes. The gel was 
kept in preserving solution and kept in 4ºC until the spots were cut out for MALDI-TOF 
analysis. 
 
2.6.2 MALDI-TOF analysis  
 Protein identification was performed by mass spectrometry using 4800 Plus 
MALDI TOF/TOF™ Analyser (Applied Biosystem, Concord, Canada). Protein spots of 
interest were excised from the silver stained gels and subjected to in-gel digestion 
according to the method of Shevchenko et al. (1996). 
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2.6.2.1 Stock solutions 
Destaining solution [15 mM Potassium ferricyanide, 50 mM sodium thiosuphate] 
 Potassium ferricyanide   0.05 g 
 Sodium thiosulphate    0.124 g 
 The solution was made up to 10 ml with MiliQ water and prepared prior to use. 
 
100 mM ammonium bicarbonate 
 Ammonium bicarbonate   0.395 g 
 The solution was made up to 50 ml with MiliQ water. 
 
Reducing solution [10 mM Dithiotreitol, 100 mM ammonium bicarbonate] 
 Dithiotreitol     0.015 g 
 Ammonium bicarbonate   10.00 µl 
Dithiotreitol (DTT) was added to 100 mM ammonium bicarbonate prior to use. 
Alkylation solution [55 mM Iodoacetamide, 100 mM ammonium bicarbonate] 
 Iodoacetamide     0.10 g 
 Ammonium bicarbonate   10.00 µl 
Iodoacetamide was added to 100 mM ammonium bicarbonate prior to use. 
 
Washing solution [50% (v/v) Acetonitrile, 100 mM ammonium bicarbonate] 
 Acetonitrile     25.00 ml 
Ammonium bicarbonate   0.0395 g 
The solution was made up to 50 ml with MiliQ water. 
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Digestion solution [7 ng/μl trypsin in 50 mM ammonium bicarbonate]  
 Trypsin     1.00 µl 
 Ammonium bicarbonate   749.00 µl 
 The solution was mixed together and made immediately prior to use. 
 
2.6.2.2 In-Gel Trypsin digestion 
Prior to in-gel digestion, the silver stained gel plug was destained by addition of 50 μl 
fresh destaining solution and shaked for 15 minutes. This step was repeated several times 
till yellowish colour of the gel plugs disappears. The gel piece was then reduced with 
reducing solution for 30 minutes at 60ºC. Then, it was alkylated with alkylation solution for 
20 minutes at room temperature (RT) in dark. The gel plug was washed with 500 μl 
washing solution for 20 minutes. The washing step was repeated for three times. 
The gel plug was then dehydrated by incubating in 50 μl of acetonitrile for 15 
minutes. After removal of solution, the gel plug was left to dry using a speed vacuum 
Model-DNA 20 (Thermo Scientific, Rockford, USA). The dried gel plug was then 
incubated overnight at 37ºC in 25 μl of digestion solution. After spinning the sample down, 
50 μl of 50% acetonitrile was added, vortexed and the sample was left at RT for 20 
minutes. The supernatant was transferred into another eppendorf tube. A hundred percent of 
acetonitrile was then added to the gel plug in order to extract the remaining protein. The 
supernatant obtained was pooled with the previous supernatant. The supernatant was 
concentrated using the speed vacuum until the final volume become half from the initial 
volume.  
 The resulting peptide solution was desalted and concentrated using zip-tips (Perfect 
Pure C18, Eppendorf, Hamburg, Germany). The mass spectrometric analyses were 
performed by mixing 1 μl of extracted sample with equal volume of matrix solution 
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consisting of 10 mg/ml alpha-cyano-4-hydroxy cinnamic acid in 0.1% (v/v) trifluoroacetic 
acid and 70% (v/v) acetonitrile. The solution was finally spotted onto the slide loader and 
was allowed to air dry. The MALDI mass spectrometry was performed using the 4800 Plus 
MALDI TOF/TOF™ Analyser. 
 
2.6.2.3 Database search 
 The Mascot programme (www.matrixscience.com) was used to search protein 
database. The programme uses peptide mass fingerprints (PMFs) to search the database for 
matching peptides from known proteins. The following parameters were used in the search: 
trypsin digests (one missed cleavage allowed), species: Homo sapiens, mass value: 
monoisotropic, peptide mass tolerance: +0.1 Da, peptide charge state: + 1and SwissProt 
database. Identification was accepted when >5 peptide masses matched to a particular 
protein (mass error +50 ppm –1 missed cleavage) and the MOWSE score was over the 
threshold score at p = 0.05. 
 
2.6.3 Gel-prep for mass spectrometry analysis by Australian Proteome Analysis 
Facility (APAF) 
 The replicate batch of gel plugs were also sent to APAF for protein identification 
using Coomassie Brilliant Blue R-250 staining as required by the facility. This was done to 
validate the protein identification done in the laboratory.  
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2.6.3.1 Stock solutions 
Fixing solution [40% (v/v) methanol and 10% (v/v) acetic acid] 
  Methanol     100 ml 
  Acetic acid    25 ml  
 The solution was made up to 250 ml by addition of distilled water. 
 
Staining solution [0.1% Coomassie Brilliant Blue R-250, 10% (v/v) acetic acid] 
  Coomassie Brilliant Blue R-250  0.25 g 
  Acetic acid    25 ml 
 The solution was made up to 250 ml by addition of distilled water. 
 
Destaining solution [10% Acetic acid] 
 The solution was made up to 1 L by addition of distilled water. 
 
2.6.3.2 Coomassie Brilliant Blue R-250 staining 
 All incubation steps of Coomassie staining were carried out with gentle agitation on 
a shaker. After completion of the electrophoresis run, the gel was immersed immediately in 
the fixing solution and left for at least 30 minutes. Fixing solution was then replaced with 
the staining solution and the gel was incubated overnight. Then, the gel was destained with 
a destaining solution. The destaining solution was changed several times until the proteins 
spots were stained with a clear background.  
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2.6.3.3 Preparation of gel plugs  
Destaining solution [200 mM ammonium carbonate, 50% (v/v) acetonitrile] 
  Ammonium bicarbonate   0.79 g 
  Acetonitile    25 ml  
 The solution was made up to 50 ml by addition of MiliQ water. 
 
Preserving solution [1% acetic acid] 
  Acetic acid    10 μl 
The solution was made up to 1 ml by addition of MiliQ water. 
 
The protein spots of interest were excised from the Coomassie stained gels and destained 
with 50 μl of destaining solution. The gel plugs were shaken for 15 minutes. This step was 
repeated several times until the bluewish colour of the gel plugs disappeared. The 
destaining solution was discarded and replace with 10 μl preserving solution. The gel plugs 
was kept in 1.5 ml tube (Eppendorf, Hamburg, Germany). The close cap of the tube was 
covered and tightens with parafilm. The gel plugs were then kept in -20˚C before being sent 
to APAF. 
 
2.7 Western blotting  
 The Western blot was used as a validation purpose to further confirm the 
differentially excreted proteins found in patients with ovarian and cervical cancer. 
Detecting the spots with antibodies also validated the identity of the proteins determined 
using MALDI-TOF/MS. The samples were resolved using two-dimensional electrophoresis 
as described in Section 2.4 before it was being transferred onto a nitrocellulose membrane 
for Western Blotting analysis. 
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2.7.1 Stock solutions 
 
Transfer buffer [48 mM Tris, 39 mM glycine, 20% (v/v) methanol] 
 
 Glycine     2.93 g 
 Tris      5.81 g 
 SDS      0.38 g 
 Methanol     200.00 ml 
The mixture was dissolved and made up to 1 L with distilled water. 
 
Tris-Buffered-Saline-Tween [100 mM Tris-HCl, pH 7.5, 0.9% Sodium chloride] 
 Tris      12.11 g 
 Sodium chloride    9.00 g 
Tris was dissolved in 900 ml distilled water and the pH was adjusted to 7.5 with 
concentrated HCl. Sodium chloride and 0.1% (v/v) Tween-20 was then added before the 
solution was finally topped up to 1 L. 
 
2.7.2 Protein transfer 
 NovaBlot Kit of Multiphor II Electrophoresis System (GE Healthcare, Uppsala, 
Sweeden) was used to transfer the proteins from 12.5% homogenous gel onto a 
nitrocellulose membrane (0.45 μm). Filter papers which were cut to the size smaller than 
the gel were soaked in the transfer buffer. Six layers of the wet filter paper were carefully 
layered one by one on a wet anode plate. The formation of bubbles between the layers was 
avoided. The nitrocellulose membrane was removed from its supporting film. The gel and 
the nitrocellulose membrane were soaked in the transfer buffer for a few minutes. The gel 
was then transferred onto the filter papers and the nitrocellulose membrane was placed on 
the top of the gel. Another six layers of filter paper were put on one by one on the gel. A 
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wet cathode plate was finally placed on the stack and the unit was run at 0.8 mA/cm², 600V 
for 1 hour except for CD59 protein which only required 30 minutes of transferring. 
 
2.7.3 Development of protein spots 
2.7.3.1 Stock solutions 
Sodium phosphate buffer (0.01 M) pH 7.2 
 Sodium phosphate dibasic dihydrate   0.01 M 
 Sodium hydrogen phosphate    0.01 M 
 Sodium chloride     0.88% (w/v) 
Sodium hydrogen phosphate and sodium chloride were dissolved in distilled water. The pH 
was adjusted to 7.4 using sodium phosphate dibasic dihydrate and the solution was made up 
to 1 L. 
 
Sodium acetate buffer (1 mM) pH 4.4 
 Sodium acetate     8.02 g/L 
 Acetic acid      6.00 g/L 
Three ml sodium acetate solution was topped up to 10 ml with acetic acid solution and the 
mixture was diluted 1:100 to give 1 mM buffer. 
 
Sodium carbonate buffer 
 Sodium carbonate     21.2 g/L 
 Sodium hydrogen carbonate    16.8 g/L 
Sodium carbonate solution was added to the sodium hydrogen carbonate to adjust the pH to 
9.5. 
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Borate buffer 
 Disodium tetraborate     0.2 M 
 Boric acid      0.1 M 
Approximately 115 ml borate solution was added to 4 L boric acid solution until the pH 
reached 7.4.  
 
2.7.3.2 Enzyme conjugation of Champedak Galactose Binding (CGB) lectin 
Futher confirmation of the altered level of fragment of inter-alpha-trypsin inhibitor 
heavy chain H4 (ITIH4) was performed using HRP-conjugated CGB lectin. To prepare the 
conjugated CGB lectin, 4 mg of horseradish peroxidase (HRP) was dissolved in 1 ml 
distilled water. Two hundred µl of 0.1 M of freshly prepared sodium periodate was added 
to the solution. The solution was stirred gently for 20 minutes at room temperature before it 
was dialysed against 0.001 M acetate buffer pH 4.4 overnight at 4˚C. Twenty µl of 0.1 M 
sodium carbonate buffer pH 9.5 was added to the HRP solution to increase the pH to 
approximately 9-9.5. One ml of the lectin solution was immediately added and the solution 
was stirred for 2 hours at RT. One hundred µl of freshly prepared 0.1 M sodium 
borohydrate was added and the solution was left to stir at 4˚C for another 2 hours. The 
conjugated lectin was then dialysed against 0.1 M borate buffer pH 7.4. An equal volume of 
60% (v/v) of glycerol in borate buffer was finally added to the solution. The solution was 
stored at 4˚C. 
 
2.7.3.3 Detection of proteins of interest using specific antibodies and HRP-conjugated CGB 
lectin 
 After the transferring process, nitrocellulose membrane was left to dry for a while. 
The membranes were blocked with 3% w/v gelatine in Tris-buffered saline (TBS), pH 7.5, 
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for 1 hour at RT and washed three times with the same buffer. They were then incubated 
for another 1 hour in the following HRP-conjugate solutions: (1) anti-human CD59 (1:5 
dilution), (2) anti-human kininogen-1 (1:500 dilution), (3) anti-albumin (1:40 dilution) and 
(4) champedak galactose binding (CGB) lectin (0.01 μg/ml) diluted/dissolved in TBST. 
The use of the CGB lectin to detect the C-terminal O-glycosylated ITIH4 fragment has 
been previously reported (Mohamed et al., 2008).  Development of the Western blot was 
performed using 25 ng 3, 3‟-diaminobenzidine and 5 μl of 30% v/v H2O2 in 50 ml TBS. 
The reaction was stopped by washing the membranes with distilled water. 
  
2.8  SELDI-TOF-MS  
 In the last few years, several “gel-free” methods have been explored, and one of it is 
surface enhanced laser desorption/ionization-time of flight–mass spectrometry (SELDI-
TOF-MS), ProteinChip Biomarker System. This is a unique approach in which peptides are 
separated on the target itself by virtue of their chromatographic properties. The sample 
drawn from the patient is applied to a protein chip, which is made up of a specific 
chromatographic surface. After several washing steps and the application of an energy-
absorbing molecule, the species that are retained on the surface of the chip are analysed via 
mass spectrometry. SELDI-TOF-MS is particularly appropriate for the investigation of low 
molecular weight proteins (<20 kDa) with femtomole sensitivity and the ability to examine 
native proteins as a complementary methods to better elucidate the protein composition of 
biological samples (Baggerman et al., 2005). The same individual samples of control 
(n=11), OCa (n=8) and CCa (n=8) which was previously analyzed with 2-DE were 
subjected to the SELDI-TOF-MS analysis. 
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2.8.1 Stock solutions 
 
Binding buffer for protein chip CM 10 array [100 mM NH4Ac, pH 4.4, 0.05% triton] 
 
 Ammonium acetate    0.3854 g 
  
 Triton      25 µl 
 
The ammonium acetate solution was made up to 50 ml with MiliQ water and the pH was 
adjusted to 4.4 before triton was added. 
 
 
Binding buffer for protein chip Q 10 array [100 mM Tris-HCl, pH 9, 0.05% Triton] 
 
 
 Tris      0.6057 g    
  
 Triton      25 µl 
 
The Tris solution was made up to 50 ml with MiliQ water and the pH was adjusted to 9 
before Triton was added. 
 
Alpha-cyano-4hydroxycinnamic acid (CHCA matrix solution) [CHCA, 50% Acetonitrile, 
0.25% Trifluoroacetic acid] 
 CHCA      5.00 mg 
 
 Acetonitrile (ACN)    100.00 µl 
 
 Trifluoroacetic acid (TFA)   0.50 µl   
  
The ACN and TFA were made up to 200 µl with MiliQ water before it was added to a vial 
containing manufacturer‟s CHCA. The mixture was centrifuged and the draw off 
supernatant was ready to be used after dilution with equal part of the similar solution. 
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Sinapinic acid (SPA matrix solution) [SPA, 50% ACN, 0.25% TFA] 
 
 SPA      5.00 mg 
 
 Acetonitrile     200.00 µl 
 
 Trifluoroacetic acid     2.00 µl  
 
The ACN and TFA were made up to 400 µl with MiliQ water and were added to the 
manufactured SPA vial. The solution was then centrifuged. The solution was prepared prior 
to use. All the matrix types were prepared according to the manufacturer‟s protocol. 
 
2.8.2 Chip preparation to be used in SELDI-TOF-MS 
The type of chips used in this analysis were the ProteinChip® CM10 arrays and 
ProteinChip® Q10 arrays (Biorad Laboratories, Hercules, USA). The ProteinChip® CM10 
Arrays incorporates a carboxylate chemistry (negatively charged) and thus acts as a weak 
cationic exchanger. Therefore, ProteinChip ® CM10 array surface binds protein that are 
positively charged at a given pH, whilst for the ProteinChip® Q10 array incorporates 
quarternized ammonium groups (positively charged) and thus acts as strong anion 
exchanger. The surface of Q10 chip binds peptides and proteins that are negatively charged 
at a given pH. These two types of protein chip were chosen to get an optimum binding of 
the whole protein in the urine sample since previous researcher had demonstrated high 
yield of protein recovery using these chips compared to the others protein chip (Papale et 
al., 2007 and Roelofsen et al., 2007) 
The protein chip array cassette (CM10 or Q10) was first placed in the bioprocessor. 
Two hundred µl binding buffer was added to the bioprocessor. The binding buffer was 
incubated for 5 minutes with agitation at 250 rpm. The buffer was then removed from the 
wells and replaced by a mixture of 160 µl binding buffer and 40 µl urine samples 
(equivalent to 80 µg proteins dissolved in MiliQ water). The solution was incubated for 30 
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minutes and the bioprocessor was covered with parafilm to avoid any contamination. After 
the incubation, the sample was removed and washed three times for 5 minutes with 200 µl 
binding buffer. Then, 200 µl of Mili Q water was added to the bioprocessor. The water was 
removed and this step was repeated once. Then, the array was left to dry and 1 µl of matrix 
solution was applied onto each spot on the chip. The spots were left to dry and the matrix 
solution was reapplied once more. The CHCA matrix solution was used for ProteinChip® 
CM10 whereas the SPA matrix solution was used with ProteinChip® Q10. Mass accuracy 
was calibrated on the day of analysis using the All-in-one peptide molecular mass standard 
(Ciphergen Biosystems, Inc., Fremont, CA, USA). 
 
 
2.8.3 Reproducibility of the spectra 
  
The reproducibility of protein spectra such as mass location and intensity between 
chips was determined from the control urinary protein samples analysed in the study. The 
protein peaks were randomly selected from five control urine samples. The selected peaks 
with m/z range of 16.742 – 16.758 and 9906.07 – 9913.98 were used as a quality control 
(QC) to calculate the coefficient of the variance (CV). The CV of peak location and 
normalised intensity were determined before the urinary protein of the control and both 
cancer patients were analysed. 
 
2.8.4 SELDI-TOF-MS Data Analysis 
2.8.4.1 Chipergen Express Data Manager 
All the chips were read by adopting the same protocol (acquisition mode: source at 
25 kV-Positive Ions,  laser energy 1500 nJ, matrix attenuation 500, focus mass 20,000 Da, 
sample rate 800 MHz, partition 1 of 4, acquired mass range from 5000 to 30,000) in the 
ProteinChip Biomarker System. ChiphergenExpress Data Manager is an application within 
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ProteinChip Biomarker System used to generate peak cluster and export these clusters into 
a file for analysis in Biomarker Patterns
TM 
Software (BPS). The software consists of Cluster 
Wizard and P-Value Wizard. In order to export a file to BPS from CiphergenExpress Data 
Manager, a new cluster was created. Since the present study used two different 
ProteinChip® array (CM10 and Q10), the set of spectra was first specified base on the 
array type condition by selecting the „array type‟ fields in the Cluster Wizard.  
CiphergenExpress Data Manager operates in two passes. The first pass uses low 
sensitivity to detect obvious and well-defined peaks, and the second pass uses low 
sensitivity settings to search for smaller peaks, with the mass values found in the first pass. 
The following parameters were used in specifying the clustering parameter for the peak 
detected (First pass: 5 S/N, Minimum peak threshold: 20% of all spectra) and cluster 
completion (Cluster Mass Window: 0.3% of Mass, Second Pass: 2 S/N). In order to 
compare control, ovarian and cervical cancer patients; the sample group was chosen as a 
field for groupings to be used in the p-value calculation under the P-Value Wizard. The 
system then prompts for a file name and location for saving the file in the .csv format. The 
variable heading for the .csv file generated by the ChiphergenExpress Software was 
labelled automatically to indicate the conditions by names starting with C0. The data in .csv 
format was then ready to be run with BPS. 
 
2.8.4.2 Biomarker Pattern Software 5.0 
 The data obtained from CiphergenExpress Data Manager was finally analysed using 
Biomarker Pattern Software 5.0 (BPS). Implementation of CART (Classification and 
Regression Trees), a statistical procedure introduced by Leo Breiman, Jerome Friedman, 
Richard Olshen, and Charles Stone in 1984 eliminates the potential problem of „overfitted 
data‟, a condition that occurs when many data points are analyzed against a relatively small 
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sample set, a situation frequently encountered in the early phases of a discovery project, 
when a relatively small number of samples may be available. 
As the name suggests, BPS is a single procedure that can be used to analyze either 
categorical (classification) or continuous (regression) data using the same technology. 
However, for SELDI-TOF-MS in this study, only classification data was used. A defining 
feature of CART is that it presents its results in the form of decision trees. The tree 
structure allows BPS handles massively complex data while producing diagrams that are 
easy to understand. 
  BPS begins with a root node (Node 1) and, through a process of yes / no 
questions, it generates descendant nodes. Some nodes are terminal; meaning that a final 
classification is reached and further splitting has no gain in data classification. The splitting 
decisions in this case were based on the normalized intensity levels of peaks from the 
SELDI protein expression profile. Each peak or cluster identified from the SELDI profile is 
therefore a variable in the classification process. Multiple classification trees were 
generated using this process, and the best-performing tree was chosen for testing. During 
the analysis, a pruning step occurs in which branches are removed and the cost of the 
removal is determined to establish a minimal tree size. This is referred to as a “learning 
set”.  
The decision tree was then subjected to cross validation. In this step, the data are 
partitioned such that randomly selected samples are categorized to ensure that the decision 
tree is valid. Cross validation is used if data are insufficient for a separate test sample. In 
such cases, BPS grows a maximal tree on the entire learning sample. This is the tree that 
will be pruned. BPS then proceeds by dividing the learning sample into 10 roughly equal 
parts, each containing a similar distribution for the dependent variable. It takes the first nine 
parts of the data, constructs the largest possible tree, and uses the remaining tenth of the 
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data to obtain initial estimates of the error rate of selected sub-trees. The same process is 
then repeated (growing the largest possible tree) on another 9/10 of the data while using a 
different tenth part as the test sample. The process continues until each part of the data has 
been held in reserve one time as a test sample. The results of the 10 mini-test samples are 
then combined to form error rates for trees of each possible size; these error rates are 
applied to the tree based on the entire learning sample. The upshot of this complex process 
is a set of fairly reliable estimates of the independent predictive accuracy of the tree. This 
allows determination of how well any tree will perform on completely fresh data, even if 
there is no independent test sample. Because the conventional methods of assessing tree 
accuracy can be wildly optimistic, cross validation is the method BPS normally uses to 
obtain objective measures for smaller data sets. 
In the present study, each split separated a parent node into exactly two child 
nodes.The terminal nodes of the peak profile were validated against the p-value generated 
from the ChiphergenExpress Data Manager. A p-value of less than 0.05 was considered to 
be significantly difference.  
 
2.8.4.3 Sensitivity and specificity of the protein of interest 
In medical diagnostics, test sensitivity is the ability of a test to correctly identify 
those with the disease (true positive rate), whereas test specificity is the ability of the test to 
correctly identify those without the disease (true negative rate). In this study, the sensitivity 
was obtained directly from the BPS software. However, the specificity was calculated 
based on the standard formula as shown as follow (Altman et al., 1994): 
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Actual Condition 
Positive Negative 
Test 
outcome 
Positive True Positive 
False Positive 
(Type I error) 
Negative 
False Negative 
(Type II error) 
True Negative 
 
↓ 
Sensitivity 
 
 =       Σ True Positive         x100 
       Σ Condition Positive 
↓ 
Specificity 
 
 =       Σ True Negative        x100               
Σ Condition Negative  
 
“Σ Condition positive” is the sum of true positive and false negative whereas “Σ Condition 
negative” is the sum of false positive and true negative. 
 
2.9 Statistical analysis 
 All values are presented as mean + SD (standard deviation). However, the 
reproducibility assessment of the 2DE gels and blots were presented as RSD (relative 
standard deviation). In Image Master 2D Platinum analysis, the percentage of volume 
contribution between control subjects and patients were determined by the software. The 
Student t-test was then used to analyse the significance of differences between control 
subjects and patients base on the percentage of volume contribution. A p-value of less than 
0.05 was considered significant. Implementation of CART in BPS, a classification 
statistical procedure was specifically used for the SELDI-TOF-MS analysis. 
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3.1 Two-dimensional electrophoresis urinary protein profiles 
 
Typical unidimensional SDS-PAGE separates proteins by their size. The drawback 
of this method is if the protein with the similar molecular weight were subjected for 
separation under the same electrophoresis, they would overlap and appear as a single band 
on the gel. 2-DE offers a better resolution and separation of the protein where they are 
separated according to their pI for the first dimension, and their molecular weights for the 
second dimension. By introducing several manipulations to the general protocol of 2-DE 
separation, the optimum condition for the separation and the reproducibility of the 
separation technique of urinary proteins were achieved. 
 The 2-DE technique performed on ovarian cancer patients (OCa), cervical cancer 
patients (CCa), and cancer negative women (control) were separated and compared. 
Reproducibility of the 2-DE separation technique was assessed by carrying out the analysis 
of each sample in duplicate. Separation of urine protein samples by 2-DE resulted in highly 
resolved profiles comprising more than 10 clusters of protein spots. Figure 4 demonstrates 
a representative urinary proteome profile obtained from a control subject.  Seven protein 
spot clusters consistently appeared in all the 15 control samples analyzed and there was no 
apparent difference in the intensity of the spots between the individual urine samples 
studied.   
 
3.2 Typical urinary protein profiles of healthy control women and patients with OCa 
and CCa 
 Urine samples of control healthy female controls, OCa patients and CCa patients 
were subjected to 2DE and silver staining. When the gel-based proteomic analysis was 
performed on urinary protein samples from OCa patients (n = 11), different 2-DE profiles 
were obtained (Figure 5, panel A). 
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                pH 3                                                                                                      pH 10 
 
Figure 4: Typical 2-DE map of urinary proteome from control subject generated by 
Silver Staining. 
Three hundred μg of purified urinary protein was dissolved with 200 μl rehydration 
solution before subjected to 2-DE using immobiline drystrip pH 3-10 followed by silver 
staining. Seven protein spot clusters consistently appeared in all the 15 control samples 
analyzed which had no apparent difference in the intensity of the spots between the 
individual urine samples studied were marked as number 2, 4, 5, 6, 7, 10 and 11. Cluster 1, 
3 and 8 are KNG1, ITIH4f and CD59, respectively. 
80 kDa 
10 kDa 
1 
2 
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(A)       (B) 
     
 
Figure 5: Typical 2-DE urinary protein profiles of patients with OCa and CCa. 
Panels A and B demonstrate the representative 2-DE urinary protein profiles of ovarian 
cancer patients (n=11) and cervical cancer patients (n=11), respectively. The aberrantly 
excreted urinary protein spot clusters were marked in circles. ITIH4f and ALBUf refer to 
fragments of inter-alpha-trypsin inhibitor heavy chain H4 and albumin, respectively. In 
contrast to the ovarian cancer patients, KNG1 was found to be insignificantly different 
when compared to the control subject although the KNG1 protein cluster pattern was much 
alike to that of ovarian cancer patients. 
 
 
 
 
KNG1 
ITIH4f 
CD59 ALBUf 
ITIH4f 
CD59 ALBUf 
  /RESULTS/ 
 
59 
 
Three protein spot clusters which consistently appeared in the control profile were either 
not detected or were reduced in intensity in the cancer patients in a considerable number of 
the patients‟ 2-DE gels.  The levels of the other protein spot clusters were comparable to 
those detected in the urinary proteome profiles of the control subjects. 
Similar to the ovarian cancer, two out of three protein spots were also found to be 
reduced or not detected in the cervical cancer patients (Figure 5, panel B). One protein spot 
appeared to be enhanced in both ovarian and cervical cancer patients. However, there were 
no significant abnormal expressed proteins found on the gels when comparing the ovarian 
cancer patients to cervical cancer patients. 
 
3.3 Image analysis of 2-DE gels   
The different altered levels of CD59, kininogen-1 and fragments of ITIH4 and 
albumin in the urine of patients with ovarian carcinoma and cervical cancer, relative to the 
controls, was confirmed when their 2-DE urine protein profiles were subjected to image 
analysis using the Image Master 2D Platinum Software 7.0.  Image analysis also confirmed 
that the levels of the other highly resolved urine protein spot clusters were comparable 
between cancer patients and controls.  Figure 6 demonstrates the mean percentage of 
volume contribution of the four urine proteins of interest in control subjects and patients 
with ovarian carcinoma. When taken as overall, the levels of CD59, KNG-1 and ITIH4 
fragment were significantly lower in ovarian carcinoma patients by 4-, 2- and 2-folds, 
respectively, compared to those excreted by the control subjects.  In contrast, the 19 kDa 
fragment of albumin appeared 10-fold higher in the patients‟ urine.   
Meanwhile, the mean percentage of volume contribution of the three urine proteins 
of interest in control subjects and patients with cervical cancer was demonstrated in Figure 
7.  
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Figure 6: Relative excretion of urinary proteins obtained from control subjects and 
patients with OCa.   
The percentage of volume contribution was determined using the Image Master 2D 
Platinum Software 7.0.  Image analysis performed on protein spot clusters that appeared 
consistently within each cohort of urine samples demonstrated the aberrant excretion of 
CD59, kininogen-1 (KNG1), ITIH4 (39 kDa fragment) and 19 kDa fragment of albumin in 
patients with ovarian carcinoma. 
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Figure 7: Relative excretion of urinary proteins obtained from control subjects and 
patients with CCa.   
The percentage of volume contribution was determined using the Image Master 2D 
Platinum Software 7.0.  Image analysis performed on protein spot clusters that appeared 
consistently within each cohort of urine samples demonstrated the aberrant excretion of 
CD59, ITIH4 (39 kDa fragment) and 19 kDa fragment of albumin in patients with cervical 
cancer. 
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When taken as overall, the levels of CD59 and ITIH4 fragment were significantly lower in 
cervical cancer patients by 11- and 3-folds, respectively, compared to those excreted by the 
control subjects.  In contrast, the 19 kDa fragment of albumin appeared 60-fold higher in 
the patients‟ urine (Table 3). The fragment of albumin was expressed in bulk in certain 
patients of cervical cancer.  
 
3.4 Identification of Aberrantly Excreted Urinary Proteins 
Subjecting the spot clusters of urine proteins that were aberrantly excreted to mass 
spectrometry and database search identified them as CD59, kininogen-1, inter-alpha-trypsin 
inhibitor heavy chain H4 (ITIH4) and albumin. Table 4 shows a summary of the data 
acquired.  High probability-based MOWSE scores were obtained for all the urinary 
proteins. Results sent to APAF for comparison purpose of proteins identification were 
tallied with in-house experiment. Among the four urinary proteins of interest, ITIH4 and 
albumin demonstrated large discrepancies between the experimental masses that were 
estimated based on their mobilities in the 2-DE gels and their theoretically calculated mass.  
This suggests that the ITIH4 and albumin spots detected in the 2-DE urinary profiles were 
truncated fragments of their native molecules.   
 Table 5 demonstrated the list of matched peptide sequences with high confidence, 
by MS/MS analysis. Sequences of peptide obtained from the MALDI-TOF-MS were then 
compared against CD59 (P13987; 128 amino acid), KNG1 (P01042; 644 amino acid), 
ITIH4 (Q14624; 930 amino acids) and albumin (P02768; 585 amino acids) in the Swiss-
Prot database. Based on the sequence and the experimental molecular weight, it is believed 
that ITIH4 and albumin are fragments of their respective proteins. 
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Table 3: Relative expression of urinary proteins analyzed by 2-DE. 
Urinary proteins 
Analysis by 2DE 
 OCa patients CCa patients 
Fold changes* p Fold changes* p 
 
CD59 - 3.60 6.3×10
-3
 - 10.95 3.95×10
-4
 
Kininogen-1 - 2.13 3.95×10
-2
 
 
n.s. n.s. 
 
ITIH
tf
 - 2.16 4.11×10
-2
 - 2.79 2.21×10
-2
 
 
Albumin
tf 
+ 10 3.58×10
-2
 
 
+ 60 4.7×10
-2
 
 
*Fold expression changes were relative to that of control values 
(–) decrease in expression; (+) increase in expression 
tf
 Truncated fragment of protein 
“n.s.” not significant  
A p value of less than 0.05 was considered significant. 
 
 
 
 
  
 
 
 
 
Table 4: Mass spectrometric identification of spot clusters from urinary protein profiles. 
 
 
 
 
 
 
 
 
 
 
 
Spot ID are as in Figure 5. KNG1, ITIH4 and ALBU refer to kininogen-1, inter-alpha-trypsin inhibitor heavy  
chain H4 and albumin, respectively.
 
 
#
 Accession numbers are from the Mascot database (www.matrixscience.com). 
* Estimation based on migration in the 2-DE gels relative to protein markers. 
Protein Accession 
number
#
 
Nominal 
mass 
(kDa) / pI 
Mean 
Experimental 
mass* (kDa)  
In house MS analysis  
 
APAF MS analysis 
MOWSE 
protein 
score 
Sequence 
coverage 
(%) 
MOWSE 
protein 
score 
Sequence 
coverage 
(%) 
CD59 P13987 14.168 / 
6.02 
19.43 160 18 108 28 
KNG1 P01042 71.912 / 
6.34 
64.34 193 15 97 39 
ITIH4 Q14624 103.262 / 
6.51 
38.85 120 7 59 2 
ALBU P02768 69.321 / 
5.92 
19.45 161 8 107 28 
/R
E
S
U
L
T
S
/ 
6
4
 
/R
E
S
U
L
T
S
/ 
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Table 5:  In house list of matched peptide sequences of high confidence identified from 
MS/MS analysis.  
Peptide sequence Ion score Amino acid 
39 kDa ITIH4 spots   
R.QGPVNLLSDPEQGVEVTGQYER.E 19 754 - 775 
K.WKETLFSVMPGLK.M 31 814 - 826 
R.RLDYQEGPPGVEISCWSVEL.- 24 911 - 930 
 
19 kDa albumin spots 
  
K.QEPERNECFLQHK.D 30 118 - 130 
K.DDNPNLPR.L 37 131 - 138 
K.YLYEIAR.R 43 162 - 168 
K.LDELRDEGK.A 10 206 - 214 
K.VHTECCHGDLLECADDR.A 41         265 - 281 
 
KNG1 spots 
   K.TWQDCEYKDAAK.A                               
   R.QVVAGLNFR.I 
   K.KYFIDFVAR.E 
   K.YFIDFVAR.E 
 
CD59 spots 
K.FEHCNFNDVTTR.L 
R.LRENELTYYCCK.K 
 
 
        46                
54 
69 
45 
 
 
85 
61 
 
 
  90 - 101 
        188 - 196 
316 - 324 
317 - 324 
 
 
   67 – 78 
   79 – 90 
 
 
   
 
Sequences of peptide obtained from the MALDI-TOF-MS were checked against CD59 
(P13987; 128 amino acid), KNG1 (P01042; 644 amino acid), ITIH4 (Q14624; 930 amino 
acids) and albumin (P02768; 585 amino acids) in the Swiss-Prot database. 
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3.5 Western blotting 
Further confirmation of the altered levels of CD59, kininogen-1 and fragments of 
ITIH4 and albumin in the urine of patients with ovarian carcinoma relative to those of the 
control subjects was performed using antisera and a lectin that bind to the respective 
proteins that were blotted onto membranes. Figure 8 demonstrates the respective 
interactions of specific antisera and the CGB lectin with the four proteins of interest in 
pooled urine samples of patients and control subjects.  In case of the 19 kDa albumin 
fragment, interaction appeared to be detected only in the pooled urine of patients with 
ovarian carcinoma compared to that of the controls, while the inverse was observed for 
CD59, kininogen-1 and the 39 kDa fragment of ITIH4. 
 
3.6 SELDI-TOF-MS analysis 
Similar to the previously reported SELDI-TOF-MS analysis (Petricoin et al. 2002; 
Adam et al. 2002), the present analysis of urinary proteins from control, OCa patients and 
CCa patients could be divided into three steps: peak detection and alignment, selection of 
peaks with the highest discriminatory power and lastly data analysis using a decision tree 
algorithm. OCa (n=8) and CCa (n=8) urine samples, that had been previously analyzed 
using two-dimensional gel electrophoresis, were used in this SELDI-TOF-MS analysis.  
Samples from controls were used as a comparison in identifying peaks corresponding to 
aberrantly expressed proteins in both cancers. 
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Figure 8: Interaction of antisera and CGB lectin with aberrantly excreted urinary 
proteins of OCa and CCa patients.  
Pooled urine samples of OCa patients, CCa patients and those of control subjects were 
subjected to 2-DE and Western blotting before being independently exposed to antisera that 
bind to CD59, kininogen-1 and albumin as well as the ITIH4-binding-CGB lectin. As for 
the CCa, kininogen-1 was not further tested since the Image Master has indicated that the 
result was not significant. 
 
 
Antiserum/lectin 
versus 
Control OCa CCa 
kininogen-1 (~64 
kDa) 
  
Not significant 
 
ITIH4 (~39 kDa) 
   
CD59 (~19 kDa) 
   
albumin (~19 kDa)  
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3.6.1 Determination of the reproducibility of the spectra 
The reproducibility of protein spectra such as mass location and intensity between 
chips was determined using the control samples. Before the analysis is done, it is important 
to verify the reproducibility of the peaks since further investigation would depend on the 
location and intensity of peak spectrum. Spectral reproducibility was evaluated according to 
relative intensity m/z. The selected peaks with m/z range of 16.742 – 16.758 and 9906.07 – 
9913.98 were used to evaluate the reproducibility of the spectra. 
 The protein peaks were randomly selected from five control samples that were 
analysed in a same day using Protein Chip® CM10 array and Protein Chip® Q10 array. 
The coefficient of variance (CV) for peak location (m/z) and normalised intensity were 
0.04% and 17%, respectively for Protein Chip® CM10 whereas the CV for Protein Chip® 
Q10 were 0.04% and 19%, respectively. Generally CV less than 20% was observed in peak 
intensity from human data analysed using SELDI-TOF-MS since peak intensity was 
typically more variable in many biological assays (Poon et al., 2007). These low 
percentages of CVs obtained from peak location and peak intensity in this study were 
within a good range and indicating high repeatability and thus validating the reproducibility 
of the peak spectra.  
 
3.6.2 Establishment of a diagnostic decision tree  
3.6.2.1 Evaluation of the classification tree quality 
Figure 9 is the representative of the control group, where the protein mixture was 
separated using ProteinChip® CM10. As soon as BPS has completed its calculation, it 
opens a window containing the resulting calculation tree topology with a visual indication 
of the tree quality (Figure 9). The tree was made of nodes with different colour ranging 
from red to blue where red is defined as better quality of classification.  
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Figure 9: A Representative of a classification tree topology for the control group. 
Control group was selected at the software navigator in order to view the classification 
quality. While the BPS was commanded to grow or prune the tree, the colour of the 
terminal node will change and indicate the quality of classification. The red is defined as 
better quality of classification and the blue as worse. The decision node is where the 
splitting occurred and designated as green squares. The nodes where the splitting ends at 
the end of each branch are known as terminal node. 
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As an example in Figure 9, by selecting the control group at the software‟s navigator 
command, the software will present a red terminal node in which the majority of cases 
selected in the nodes were the control samples. While the BPS was commanded to grow or 
prune the tree, the color of the terminal node will change and indicate the quality of 
classification.  Thus, the tree quality which is its ability to differentiate between the three 
cohorts, could be evaluated by using the software‟s navigator command. 
 
 
3.6.2.2 Cross validation 
Cross validation is a statistical method of evaluating and comparing learning 
algorithms by dividing data into two segments: one used to learn and train a model and the 
other used to validate the model (Payam et al., 2009). As the classification tree built in this 
study, may demonstrate adequate prediction capability on the learning data, it might fail to 
predict future unseen data (Larson, 1931). Although the number of sample in this study was 
low, it was enough to construct the classification tree. However, a blind test could not be 
performed to validate the constructed tree, but the performance of the tree could still be 
estimated by having cross validation procedure calculated automatically by the BPS. 
 The BPS started with growing the tree to the largest maximal tree possible and 
prunes away until it finds the best tree. The resulting decision tree which referred as 
„learning‟ set was then subjected to cross validation. In this step, the data are partitioned 
such that randomly selected samples are categorized to ensure that the decision tree is valid. 
The error curve graph shown in Figure 10 demonstrates the cross-validated relative cost or 
misclassification cost generated by the application while pruning the tree. It indicated a 
good classification was obtained where the graph demonstrated the rate of misclassification 
to go down as the tree gets progressively larger.  
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Error Curve 
 
 
 
Figure 10: A representative of error curve from control group 
An error curve graph of the control group displaying the cross validated relative cost versus 
the number of terminal nodes for each tree size in the nested sequence. The cost validated 
relative cost is known as the misclassification cost generated while pruning the tree. The 
misclassification rate went down as the tree gets progressively larger. 
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3.6.3 Identification of the biomarker pattern and the construction of diagnostic model 
separate by ProteinChip® CM10 
Four peaks, with m/z of 8828.8, 7528.7, 5393.9 and 6176.7 in Figure 11 were the 
best determinant of the decision tree. At Node 1 (defined by peak 8828.8), one control, one 
ovarian cancer patient and seven cervical cancer patients with peak intensities lower than 
26.199 µA were classified into Terminal Node 1. The other 18 samples were further 
classified at Node 2 (defined by peak 7528.7), where six ovarian cancer patients with peak 
intensities of 34.199 µA or less were classified to Terminal Node 2. The other 12 samples 
entered Node 3 (defined by peak 5393.8), where one cervical cancer patient with peak 
intensities of 3.644 µA or less went to Terminal Node 3. The other 11 samples were further 
classified at Node 4 (defined by peak 6176.7), where ten controls with peak intensities of 
75.928 µA or less went to Terminal Node 4. The remaining one sample, which was from 
ovarian cancer patient, was classified to Terminal Node 5. Overall, the model correctly 
classified 10 out of 11 control and seven out of eight ovarian cancer samples. Interestingly, 
it was abled to classify all eight cervical cancers samples correctly.   
 
3.6.4 Identification of the biomarker pattern and the construction of diagnostic model 
separate by ProteinChip® Q10 
Figure 12 showed four peaks with m/z of 5937.1, 6186.2, 6349.5 and 15802 which 
were the best determinant of the decision tree. At Node 1 (defined by peak 15802), five 
ovarian cancer patients with peak intensities higher than 14.468 µA were classified into 
Terminal Node 6. The other 22 samples with peak intensities lower than 14.468 µA were 
further classified at Node 2. The population was further divided based on the peak intensity 
of 4.482 µA. Interestingly, all five samples which fall under Terminal Node 5 were  from 
cervical cancer  cohort. The remaining  17  samples   were  further classified at Node 3 
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Figure 11: The decision tree of samples upon separation of protein by ProteinChip® 
CM10 arrays. 
A tree structure of the classification model was generated to classify the OCa, CCa and 
control samples based on the peaks separated by the ProteinChip® CM10 Arrays. In the 
hierarchy rectangles, the presence or absence of three SELDI-TOF-MS peaks, with m/z 
value of 8828.8, 7528.7, 5393.9 and 6176.7 serves as parent nodes to classify samples in a 
hierarchical way. The threshold value which was shown by the m/z value following the 
peak intensity was where the splitting occurred. Samples were classified into a lower level 
node until the final classification was reached. For example, C08828_8, which is the 
intensity of the peak, observed in the data indicated the conditions of variable for m/z 
8828.8.  
  /RESULTS/ 
 
74 
 
 
Figure 12: The decision tree of samples upon separation of protein by ProteinChip® 
Q10 arrays. 
A tree structure of the classification model was generated to best classify the OCa patients, 
CCa patients and control samples using ProteinChip® Q10 Arrays. In the hierarchy 
rectangles, the presence or absence of three SELDI-TOF-MS peaks, with m/z value of 
5937.1, 6186.2, 6349.5 and 15802.0 served as parent nodes to classify samples in a 
hierarchical way. Samples were classified into a lower level node until the most correct 
classification was achieved in the terminal nodes. 
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(defined by peak m/z 6349.5), where two controls and three ovarian cancer samples with 
peak intensity lower than 10.655 µA were classified into Terminal Node 1. The other 12 
samples entered Node 4 (defined by peak m/z 5937.1), where two cervical cancer samples 
with peak intensities of 1.86 µA or less went to Terminal Node 2. At Node 5 (defined by 
peak m/z 6186.2) one cervical cancer sample with peak intensity lower than 10.729 µA 
entered Terminal Node 3 and the remaining nine samples of control healthy women with 
peak intensity higher than 10.729 µA were classified to Terminal Node 4. Overall, from 27 
samples, the model classified them into nine controls, ten ovarian cancers and eight cervical 
cancers. 
 
3.6.5 Spectrum of control, OCa and CCa samples 
The p-value of the protein peaks in the terminal nodes of the classification tree were 
obtained from the Chipergen Express Data Manager (Table 6). It was calculated base on the 
peak intensity of the proteins from OCa, CCa and control. The peaks of m/z 7528.7 and at 
m/z 8828.8 obtained at the terminal node of the classification tree using ProteinChip® 
CM10 Arrays were found to be significantly different. Only one protein, which is peak at 
m/z 15802, was found to be significantly different in the classification tree obtained from 
the separation of ProteinChip® Q10. 
Figure 13 is the representative mass spectrographic profile showing the m/z 8828.8 
peak which was aberrantly excreted in seven CCa patient with p-value 0.03 when compared 
to both OCa and control samples. Representative of spectra for 7528.78 peak is shown in 
Figure 14. The abnormally excreted protein was detected in 6 OCa samples with p-value 
less than 0.01 when compared to both CCa patients and control samples. Figure 15 is the 
representative mass spectrographic profile reveals higher intensity of m/z 15802 peaks in  
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Table 6: Statistical analysis of protein peak intensity from  
OCa, CCa and control by Chipergen Express Data Manager. 
 
Protein peaks from ProteinChip® CM10   
m/z P value 
5393.9 0.70 
6176.7 0.18 
7528.7 0.01 
8828.8 0.03 
  Ptotein peaks from ProteinChip® Q10   
m/z P value 
5937.1 0.11 
6186.2 0.11 
6349.5 0.18 
15 802 0.01 
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(A) Control 
 
            
 
(B) Ovarian cancer patient 
 
 
            
  
(C) Cervical cancer patient 
 
 
          
 
Figure 13: SELDI-TOF-MS spectra showing peak m/z 8828.8 of control, OCa and 
CCa samples using ProteinChip® CM10 array. 
Panel A, B and C are the representative mass spectrographic profile showing the m/z 8828.8 
peak which was aberrantly excreted in seven cervical cancer patient with p-value less than 
0.05 when compared to both OCa and control samples. Arrow show no peak detected in 
sample, indicating that less protein is excreted in CCa patients.  
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(A) Control 
 
    
 
 
(B) Ovarian cancer patient 
 
     
 
 
 
(C) Cervical cancer patient 
 
  
                   
 
Figure 14: SELDI-TOF-MS spectra showing peak m/z 7528.78 of control, OCa and 
CCa samples using ProteinChip® CM10 array. 
Panel A, B and C are the representative mass spectrographic profile showing the m/z 
7528.78 peak which was aberrantly excreted in six ovarian cancer patient with p-value less 
than 0.05 when compared to both CCa and control samples. Arrow show no peak detected 
in sample, indicating that less protein is excreted in OCa patients. 
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(A) Control 
 
 
       
(B) Ovarian cancer patient 
         
        
(C) Cervical cancer patient 
 
                
 
Figure 15: SELDI-TOF-MS spectra showing peak m/z 15,802 of control, OCa and 
CCa samples using ProteinChip® QM10 array. 
Panel A, B and C are the representative mass spectrographic profile showing the m/z 15802 
peak which was aberrantly excreted in five ovarian cancer patient with p-value less than 
0.05 when compared to both CCa and control samples. Arrow show high peak detected in 
sample, indicating that the protein is excreted more in OCa patients. 
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five ovarian cancer patients with p-value of 0.01 compared to both cervical cancer patients 
and control peaks. On average, the peak intensity in ovarian cancer samples were about 30 
µA but it was hardly detected in cervical and control samples. 
 
3.7 Sensitivity and specificity of the tree summary report 
To validate the sensitivity value obtained from the BPS software, it was recalculated 
using the formula (Altman et al., 1994) in section 2.8.4.3. The sensitivity value obtained 
from the software was similar with the value calculated using the formula. The specificity 
was calculated based on the formula reported by Altman et al., (1994) since the specificity 
value was not given by the BPS software. Table 7 and Table 8 demonstrate the sensitivity 
and specificity of the learning set and test set of the diagnostic decision tree of the protein 
peaks separated by CM10 ProteinChip® array and Q10 ProteinChip® array, respectively.  
Referring to Figure 11, the four peaks at m/z 5393.9, 6176.7, 7528.7, and 8828.8 
were used to generate the classification tree to classify the three cohorts. Based on the tree, 
19 out of 27 samples were correctly classified as no-ovarian cancer, where the specificity of 
the classification method was 100%. However, the sensitivity was only 87.5% since one of 
the OCa sample was misclassified as cervical cancer. Unlike the CCa samples, the tree 
manage to classify all the eight cervical cancer thus, achieved the sensitivity of 100%. 
However, the specificity was only 89.47% since two samples belong to control and OCa 
was also classified as cervical cancer (Table 7). 
  The cross validation which generate the test set had correctly classified five out of 
eight ovarian cancer samples and nine out of nineteen non-ovarian cancer samples. As for 
the cervical cancer, the test set had correctly classified three out of eight cervical cancer 
samples and eleven out of 19 no-cervical cancers. These results yielded sensitivity of 
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62.5% and specificity 47.36% for the ovarian cancer whereas sensitivity of 37.5% and 
specificity of 57.9% for the cervical cancer test set (Table 7). 
Referring to Figure 12, the four peaks at m/z 5937.1, 6186.2, 6349.5 and 15802 
were used to generate the classification tree to classify the three cohorts. Based on the tree, 
eight out of 27 samples were classified as ovarian cancer, where the sensitivity of the 
classification method was 100%. However, the specificity was only 89.5% since two out of 
the 19 no-ovarian cancer samples were misclassified as ovarian cancer. Interestingly, 100% 
sensitivity and 100% specificity were achieved by this classification model to correctly 
classify all the eight cervical cancer and 19 no-cervical cancers samples.  
For the test set, four out of eight ovarian samples were correctly classified and five 
out of 19 true non-ovarian cancer yielded sensitivity of 50% and specificity of 26.3%. As 
for the test set on cervical cancer patients, one out of eight cervical cancer samples and 
eight out of 19 non-cervical samples were correctly classified. These result yielded 
sensitivity of 12.5% and specificity of 42.1% (Table 8). The summary of the prediction 
result of the diagnostic model of its sensitivity and specificity for ovarian cancer and 
cervical cancer were shown in Tables 7 and 8. 
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Table 7: The prediction results of the diagnostic model for ovarian cancer  
and cervical cancer separated by ProteinChip CM10. 
 
   Group Sample Cases Correctly 
classified 
samples* 
Classification 
Accuracy 
(%) 
     
Learning 
set 
Ovarian cancer 
 
8 
 
7 
 
87.5
a 
 
No-ovarian-cancer 19 19 100
b 
 
 
 
   
Test set 
Ovarian Cancer 
 
8 
 
5 
 
62.5
a 
 
No-ovarian-cancer 
 
19 
 
9 
 
47.4
b 
 
     
Learning 
set 
Cervical cancer 
 
8 
 
8 
 
100
a 
 
No-cervical-cancer 19 17 89.47
b 
 
 
 
   
Test set 
Cervical Cancer 
 
8 
 
3 
 
37.5
a 
 
No-cervical-cancer 
 
19 
 
11 
 
57.9
b 
 
     
*
Correctly classified: Number of samples that were correctly classified by the BPS 
a 
Sensitivity 
b
 Specificity 
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Table 8: The prediction results of the diagnostic model for ovarian cancer  
and cervical cancer separated by ProteinChip Q10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*
Correctly classified: Number of samples that were correctly classified by the BPS 
a 
Sensitivity 
b
 Specificity 
 
 
 
 
Group Sample Cases Correctly 
classified 
samples* 
Classification 
Accuracy 
(%) 
     
Learning 
set 
Ovarian cancer 
 
8 
 
8 
 
100
a 
 
No-ovarian-cancer 19 17 89.5
b 
 
 
 
   
Test set 
Ovarian Cancer 
 
8 
 
4 
 
50
a 
 
No-ovarian-cancer 
 
19 
 
5 
 
26.3
b 
 
     
Learning 
set 
Cervical cancer 
 
8 
 
8 
 
100
a 
 
No-cervical-cancer 19 19 100
b 
 
 
 
   
Test set 
Cervical Cancer 
 
8 
 
1 
 
12.5
a 
 
No-cervical-cancer 
 
19 
 
8 
 
42.1
b 
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4.1 Proteomic analysis and urinary protein profiles 
 
Studies on urinary proteome using different approaches had been previously 
demonstrated. For example, through the use of HPLC-ESI-MS technique, several peptides 
and protein fragments had been identified (Heine et al., 1997). Common analytical methods 
used in study urinary proteome includes SELDI-TOF-MS (Papale et al., 2007), microarray 
(Liu et al., 2009) and capillary electrophoresis coupled to mass spectrometry (CE-MS) 
(Zürbig et al., 2009). However, two main approaches, which are 2-DE and SELDI-TOF, 
have been used to establish a normal human urinary proteome (Jose et al., 2007) and 
formed the basis for the choice of the techniques used in this study.  
In this present study, 2-DE with MS identification and SELDI-TOF were adopted 
for the screening of diseased and non-diseased individuals. 2-DE was preferred in this study 
due to its high resolution capacity, which is very important for proteome analysis. It is also 
applicable in the studies requiring the quantitative analysis of a differential proteome, for 
example identifying specific protein features between normal and breast malignant cells 
(Stein & Zvelebil, 2002).  
SELDI-TOF technique on the other hand, is preferred because of its reproducibility 
and its capacity to permit rapid comprehensive large-scale analysis of individual proteins 
within complex protein mixtures. By using stationary phase, different sample complexity 
can be reduced which also allow the detection of lower abundance proteins (Lin et al., 
2004). SELDI-TOF allows integral protein profiling from a variety of complex biological 
materials such as serum, blood, plasma, tissue, urine, saliva and cell lysis products with 
limited sample preparation. It is more sensitive, rapid and requires smaller amounts of 
sample compared to other proteomics methods (Ionela, Radu, & Elena, 2010). 
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4.1.1 Optimization in sample collection and sample preparation 
The concern of getting a good urinary proteome map started from the beginning of 
the whole process especially during the sample collection. In order to ensure that the 
sample was optimally preserved from bacterial growth throughout the whole project, 20 
mM sodium azide was added to the urine upon the sample collection. Although 
preservative had been added, the contaminant in the urine samples had to be removed. The 
purpose of centrifugation at 10,000 rpm was to remove contaminant cells and cell walls, 
microorganism and debris. These contaminants would also interfere with the proteome 
profile by giving dubious spots with consequences of leading to the wrong analysis. The 
supernatant was then dialysed in order to reduce the salt concentration which would 
interfere with isoelectric focusing.  
 According to Thongboonkerd et al., in 2007, overgrown bacteria can lead to the 
additional spots in 2-DE and the increased amount of total protein. They had systematically 
evaluated the optimum concentration of preservatives and temperature condition which 
could delay the bacterial growth. Addition of 10 mM sodium azide or 200 mM boric acid as 
preservative would delay the bacterial growth up to 48 hours upon storage at RT or 4˚C. 
They also demonstrated that, by keeping the samples at 4°C, there was no bacterial 
overgrowth observed in the centrifuged samples in the presence of a preservative at 0.1-10 
mM sodium azide and 2-200 mM boric acid. 
Another controversial subject was the large inter-subject variation in 2-DE urinary 
protein profiles which made it difficult to establish a normal human urine 2-DE proteome. 
In this whole study, the urine samples were analyzed individually in 2-DE analysis except 
for the Western blot technique. It was important to subject the urine sample individually to 
the 2-DE instead of pooled samples because any extra protein spot that belongs to the 
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individual urinary sample could be observed in the individual. By employing the statistical 
analysis, the extra protein spot would become insignificant.  
 
4.1.2 Urinary proteome map 
Figure 4 and 5 were the representative urinary proteome map for healthy control 
women, ovarian and cervical cancer patients where the protein loaded to the 2-DE analysis 
were optimized as 300 µg. Being a filtrate of blood, urine also contains protein components 
similar to that of serum (Barrat and Topham, 2007).  Thus, abnormalities that can be 
detected in the serum could also be detected in the urinary proteome. However, unlike 
serum sample, the concentration of protein in the urine varies broadly in each healthy 
individual. The concentration of urinary protein from healthy control women obtained in 
this study was approximately from 38-70 μg/ml. The amount of protein excreted per day by 
normal adults is usually given as less than 150 mg per 24 h (Castleman 1974; Diem et al., 
1962) and comparable to the range obtain from healthy control in the present study.  
As for the ovarian and cervical cancer patients, the concentration of urinary protein 
was around 259-2091 μg/ml and 156–1918 μg/ml, respectively. The higher concentration of 
protein in both diseases were expected because elevated plasma protein levels is commonly 
associated with most pathological condition, and often mirrored in the urine as a result of 
glomerular filtration of small circulating protein and peptide markers that can pass through 
the glomerular filter (Barrat and Topham, 2007). However, no research has focused on the 
association of proteinuria with the two cancers although this was observed in some cancers 
such as multiple myeloma and bladder cancer (An, 2011). It is important to note that the 
two cancers had been known to spread to other parts and particularly the bladder which 
could partly explain the proteinuria in their study. The individual is considered proteinuria 
when the concentration of the proteins found in the urine is more than 200 µg/ml. 
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4.1.2.1 Comparison of the proteome map with previously published data 
Figure 4 demonstrates a representative urinary proteome profile obtained from a 
control subject. In the present study, separation of urinary protein samples by 2-DE resulted 
in highly resolved profiles comprising more than ten clusters of protein spots. Seven 
protein spot clusters consistently appeared in all the 15 control samples analyzed and there 
was no apparent difference in the intensity of the spots between the individual urine 
samples studied.  
Protein clusters labelled 1 to 4 in the control urinary proteome in this study were 
observed in previously published urinary proteome (Anderson et al., 1979; Thongboonkerd 
et al., 2002; Pieper et al., 2004; Thongboonkerd et al., 2005; Laurence et al., 2011). These 
proteins were commonly observed since the first proteomic study of normal urine 
performed in 1979 although at that time the term proteomics had not been established. 
In the present study, the protein identification was not performed for all the protein 
spots or clusters on the proteome map since the main aim for this project was to detect and 
identify the abnormally or aberrantly excreted proteins. However, based on the protein 
identification using MALDI-TOF-MS in previous studies, the protein clusters labelled 2 
and 4 were believed to be zinc alpha-2 glycoprotein and alpha-1 microglobulin respectively 
(Pieper et al., 2004). 
Protein cluster labelled 5 in this study were also believed to consist amylase, alpha 
1A, amylase alpha 2A and Chaperon containing TCPI, subunit 6A when compared to the 
study by Thongboonkerd et al., in 2002. This protein cluster was also identified in samples 
obtained from healthy male and female donors which were fractionated into native proteins 
higher and lower than 30 kDa using size exclusion chromatography (SEC) column (Pieper 
et al., 2004).  
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The widely separated cluster 7 consists of albumin fragment, agrin fragment, post-
translationally modified of prostaglandin-H2 D-isomerase and caspase 10 fragment (Pieper 
et al., 2004). Previously, cluster 7 were claimed to consist immunoglobulins light chains 
too (Anderson et al., 1979; Edward et al., 1982). The presence of Ig gamma-1 chain C 
region and Ig gamma-3 chain C region in the urine were proven using LC-MS-MS for 
protein identification (Pieper et al., 2004). However, the positions of these proteins at 
cluster 7 were doubted since the molecular weights of these proteins reported by Piper et 
al., (2004) were much smaller than what was suggested by the Swiss-Prot database unless 
the peptide detected was a fragment of the protein. Protein spot 9 in the present study was 
believed to be fibrinogen beta chain fragment (Pieper et al., 2004). 
 
4.2 Image analysis of 2-DE, protein identification and validation of the identified 
proteins 
 The altered level of proteins in the urine of patients with ovarian carcinoma and 
cervical cancer, relative to the controls was confirmed when their 2-DE urine protein 
profiles were subjected to image analysis using the Image Master 2D Platinum Software 
7.0. Image analysis also confirmed that the levels of the other highly resolved urine protein 
spot clusters were comparable between the two cohorts.  
Figure 6 demonstrated the mean percentage of volume contribution of the four 
urinary proteins of interest in control subject and patients with ovarian carcinoma. On the 
other hand, Figure 7 demonstrated the mean percentage of volume contribution of the three 
urinary proteins of interest in control subjects and patients with cervical cancer. Table 3 
demonstrated that most of the proteins namely CD59 and ITIH4 fragment were down 
regulated in the ovarian carcinoma and cervical cancer but albumin fragment was appeared 
to be higher in both ovarian and cervical cancer patients when compared to the control. 
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Although the albumin fragment was appeared 4-fold higher in cervical cancer patients 
when compared to the ovarian cancer patients, the different was not significant. 
 The spot clusters of urinary proteins that were aberrantly excreted were then 
subjected to mass spectrometry and database search for protein identification. Table 4 
shows a summary of the data acquired. The database searched identified them as CD59, 
kininogen-1, inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4) and albumin. The other 
set of similar aberrantly excreted urinary proteins samples sent to APAF for comparison 
purposes, also gave similar identification.  
Table 5 demonstrated the list of matched peptide sequences of high confidence 
identified from MS/MS analysis. In this study, the identification of the proteins was 
successfully done with the MOWSE protein score greater than 69 which is the value 
considered significant by the MASCOT database searches. Among the four urinary proteins 
of interest, ITIH4 and albumin demonstrated large discrepancies between the experimental 
masses that were estimated based on their mobilities on the 2-DE gels and their 
theoretically calculated mass. This suggested that the ITIH4 and albumin spots detected in 
the 2-DE urinary protein profiles were truncated fragments of their native molecules. 
In the case of ITIH4 (Q14624), the peptide sequences identified with high 
confidence from the MS/MS correlated to the C-terminal region of the protein, when they 
were checked against the Swiss-Prot database.  Sequences obtained were those that spanned 
within the kallikrein-generated 35 kDa fragment region of ITIH4 (amino acids 696-930).  
However, molecular mass estimation based on its relative mobility in 2-DE gels indicated a 
larger fragment of approximately 39 kDa.   
In the case of KNG1, high-molecular-weight kininogen (HK) and low-molecular-
weight kininogen (LK) proteins are the two isoforms produced by alternative mRNA 
splicing in human (Takagaki et al., 1985; Kitamura et al., 1985). Although in the present 
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study demonstrated the molecular weight of KNG1 was 64.34 kDa which is the size 
normally observed in LK (Sainz et al., 2007), the important sequence which differ the HK 
and LK proteins was not observable.  
LK could be distinguished from HK by observing the LK sequence at position 402-
427, VSPPHTSMAPAQDEERDSGKEQGHTR in HK which is replaced by 
SHLRSCEYKGRPPKAGAEPASEREVS in LK. Apart from that, LK protein is shorter 
than the HK because of the missing sequence at 428-644 during the alternative mRNA 
splicing (www.uniprot.org). Based on the MALDI-TOF-MS/MS for KNG1 sequence in 
this study, it could not be determined whether the HK or LK isoform was present since the 
sequence from 402-427 was not detected by the MS/MS.  
Figure 8 in this study showed further confirmation of the altered levels of CD59, 
kininogen-1 and fragments of ITIH4 and albumin in the urine of patients with ovarian 
carcinoma relative to those of the control subjects was performed using antisera and a lectin 
that bind to the respective proteins that were blotted onto membranes. The interactions of 
proteins demonstrated in pooled control, ovarian and cervical cancer patients validated the 
identification of proteins obtained from MALDI-TOF-MS/MS. In case of the 19 kDa 
albumin fragment, interaction appeared to be detected in the pooled urine of patients with 
ovarian carcinoma and cervical cancer compared to that of the controls, while the inverse 
was observed for CD59, kininogen-1 and the 39 kDa fragment of ITIH4.  
Unlike other proteins which interacted with the commercial antisera, ITIH4 was not 
detected by the antibody. It is probably due to the loss of epitope recognized by the 
antibody when the protein was fragmented. This is supported by the fact that the antibody 
could detect the 103 kDa ITIH4 but not the 39 kDa fragment. To overcome the problem in 
this study, CGB lectin was used to detect the C-terminal O-glycosylated ITIH4 fragment 
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(Mohamed et al., 2008) and the results obtained validates the decrease in the excretion of 
the ITIH4 fragment as observed in silver stained 2-DE profile. 
 
4.3 Compliment Regulatory Protein CD59 
The CD59, which was found to be down regulated in the urine of OCa and CCa 
patients, is a membrane glycoprotein that functions to inhibit membrane attack complex 
(MAC) by binding to C5b-8 complex and thus inhibiting the recruitment of C9 (Lachman, 
1991). Thus, CD59 plays an important role in inhibiting the lysis of normal self cell by 
complements during the process of inflammations. CD59 is anchored to the cell membrane 
through glycophosphotidylinositol which is linked to the C-terminal residue Asn-77 (Meri 
et al., 1990). The soluble form of CD59 can normally be found in urine with the 
concentration of 3.7 µg/ml (Lehto et al., 1995). However, the soluble form could hardly be 
detected in the serum or plasma but through addition of detergent to the serum or plasma, 
the concentration of 33-119 ng/ml CD59 could be detected using ELISA assay (Landi et 
al., 2003). This might explain why the association of serum CD59 and cancer has not been 
reported although the differential expression of CD59 on tumours (Madjd et al., 2003; 
Watson et al., 2006) and in urine (Week et al., 2008; Kreunin et al., 2007) was 
documented. Since the CD59 was hardly being detected in the serum, it was an advantage 
to use urine as a sample for the detection of the CD59 protein. 
Like the normal cells, cancer cell lines of the breast (Ellison et al., 2007), lung 
(Zhao et al., 2009) and ovary (Bjorge et al., 2005) which express CD59 were shown to 
resist the lysis by complements when the cells were exposed to specific monoclonal 
antibody. Therefore, it is possible that the expression of CD59 and other complement 
regulatory proteins on cancer cells can inhibit the elimination of the cancer cells through 
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classical complement pathway or antibody-dependent cell-mediated cytotoxicity (ADCC) 
and allow the cells to develop into more malignant cells. Although the in vitro study seems 
to suggest the expression would be beneficial to the cancer cells, the analysis on the 
colorectal cancer cells however, showed the higher expression of CD59 in earlier stages of 
tumour and then the expression decreases in poorly differentiated and metastasised cells 
(Watson et al., 2006). The correlation of the expression in the urine samples and the 
progress of the diseases are yet to be determined. 
Although similar reduced excretion of the protein had previously been reported in 
the urine of patients with bladder cancer (Kreunin et al., 2007) and pancreatic ductal 
adenocarcinoma (Week et al., 2008), the decrease in expression of CD59 in urine of 
patients with cervical cancer and ovarian carcinoma was never reported previously. The 
reason for the low levels of CD59 in the urine of cancer patients is not understood. One 
possibility is that since the turnover of cancer cells bearing CD59 is low as they are 
generally “immortal”, less of the cell surface molecules are being solubilized and excreted 
in the urine. However, this remains to be further proven. 
 
4.4 Kininogen-1  
 Like CD59, kininogen-1 was also detectable in the urine of healthy individuals. 
Previous studies performed on serum and plasma samples have shown that the expression 
of kininogen-1 was significantly reduced in patients with gastrointestinal cancer (Roeise et 
al., 1990 ), breast cancer (Doustjalali et al., 2004) and two different types of cervical cancer 
(Abdul-Rahman et al., 2007). Since kininogen-1 is known for its antiangiogenic properties 
and inhibitory action on the proliferation of endothelial cells (Liu et al., 2008), its lowered 
expression in serum or plasma of the cancer patients was believed to have contributed to 
the survival of the cancer cells (Abdul-Rahman et al., 2007).  
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In view of these previous reports, it was not surprising to find similar reduced levels 
of kininogen-1 in the urine of patients with ovarian carcinoma (figure 6). However, the 
aberrant kininogen-1 expression is apparently not cancer-specific since decreased levels of 
the protein had previously been reported in the urine of patients with chronic pancreatitis 
(Weeks et al., 2008), interstitial cystitis (Canter et al., 2008) and IgA nephropathy 
(Rocchetti et al., 2008), although the cause for the altered levels of kininogen-1 in these 
diseases may have been different. 
The role of KNG1 either is inducing angiogenesis or apoptosis, which leads to the 
inducing or inhibiting cancer, remains unclear since the molecular mechanisms involved 
both process are extremely complex (Carmeliet et al., 2001; Eliceiri et al., 2001; Folkman 
et al., 1995). However, it was shown previously that Brown Norway-Katholiek (BN-Ka) 
rats, which lack of kininogen due to a single mutation, could not generate bradykinin and 
display decreased in angiogenesis (Hayashi et al., 2002). Interestingly, administration of a 
bradykinin analog to BN-Ka was shown to promote angiogenesis associated to the 
upregulation of the Vascular Endothelial Growth Factor (Ku et al., 1993, Hayashi et al., 
2002). Another study directly displayed that daily injection of KNG1 to BN-Ka rats 
enhance angiogenesis (Ikeda et al., 2004). It is possible that the decrease in kininogen-1 
excretion in urine is due to the increase of its usage for cancer survival.   
 Although KNG1 was also less excreted in the urine of cervical cancer patients, it 
was statistically not significant (Table 3). Previously, the KNG1 in the serum of squamous 
cell cervical carcinoma and cervical adenocarcinoma were found as 0.01 and 0.3 fold 
decrease in expression when compared to the control (Abdul-Rahman et. al., 2007). This 
slight different found in the serum might explain the reason why the analysis in the urine 
was not significant. Thus, a higher number of cervical cancer specimens may be required 
for a statistical analysis in confirming the present data.  
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4.5 Inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4) 
 ITIH4 which may be involved in acute phase reactions or endopeptidase inhibitory 
functions, were detected in low levels in patient‟s urine of ovarian carcinoma and cervical 
cancer as shown in figure 6 and figure 7. The estimated molecular mass of the urine ITIH4 
fragment indicated that it was slightly larger than its reported 35 kDa serum counterpart in 
the ovarian carcinoma patients (Mohamed et al., 2008). Detection of the different sizes of 
ITIH4 fragments was not surprising as previous study using SELDI-TOF-MS have 
demonstrated that ITIH4 was extensively processed within its proline-rich region in the 
human serum. In different diseases including ovarian carcinoma, different fragments were 
shown to be proteolytically generated (Song et al., 2006). It was confirmed that the 
sequence found in the urine samples was similar with the sequence of 35 kDa ITIH4 based 
on the MALDI-TOF-MS analysis.  
While the present study demonstrated the reduced levels of the 39 kDa ITIH4, 
fragment in the urine of patients with ovarian carcinoma and cervical cancer, the previous 
data showed the up-regulated levels of a 35 kDa ITIH4 fragment in the serum samples of 
the patients (Mohamed et al., 2008). This inverse relationship and the difference in the 
molecular masses of the ITIH4 fragments detected in the respective samples suggest 
presence of a selective glomerular filtration mechanism that retained the 35 kDa fragment 
in the blood but allowed its 39 kDa counterpart to be excreted in the urine. The 39 kDa 
ITIH4 in the urine can be further validated and confirmed by doing the amino acid 
sequencing in order to see the actual location of the cleavage. 
 The precise reason for the reduced levels of the ITIH4 fragment in the urine of the 
patients is not understood. However, ITIH2, ITIH3, ITIH4 and ITIH5 with exception of 
ITIH1 were found to be downregulated in a variety of human solid tumours investigated in 
the differential gene expression of the ITIH gene family (Hamm et al., 2008). ITIH2 was 
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previously studied profoundly and associated to the breast cancer (Hamm et al., 2008), 
while ITIH4 was found to be less excreted in ovarian and cervical cancer patients in the 
present study. ITIH4 gene expression was also found to be down regulated in ovarian 
cancer tissue previously suggesting that certain ITIH protein expression might be specific 
towards certain cancer diseases.  
 
4.6 Albumin 
Based on their resolved locations in the 2-DE gels and MS/MS derived sequences, 
the enhanced albumin spots detected in the urine of ovarian carcinoma and cervical cancer 
patients in this study (figure 6 and 7) appeared to be an albumin fragment with the amino 
acid sequence positions 118 to 281, and with an approximate molecular mass of 19 kDa as 
shown in Table 5. The human urine is known to contain low levels of albumin fragments, 
with some polypeptides containing discontinuous sequences joined by unknown crosslinks 
(Hortin et  al., 2008).  
Up until now, there are several groups suggesting the potential of albumin as a 
cancer biomarker. Mider et al. in 1984 was the first to report that albumin might be 
involved in tumour nutrition by concluding that tumour acts as a nitrogen trap after 
comparing the protein metabolism in normal and tumour tissue. Later, it was demonstrated 
that albumin entered the tumour cells by pinocytosis (Ryser et al., 1963). 
 A group of researchers had extensively studied the involvement of albumin by 
systematically demonstrating that the tumour is the major site of albumin catabolism (Sinn 
et al., 1990; Schilling et al., 1992). Furthermore, Roger et al., (1989) showed that the 
residualizing radiolabeled albumin uptake increased not only in ovarian tumour-342, but 
also in other cases such as Walker-256 carcinoma, Novikoff hepatoma, Dunning prostatic 
and C6 glioma. 
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The increase in excretion of albumin fragment found in the urine of patients with 
ovarian and cervical cancer in this study was most probably due to the by products or waste 
from the albumin catabolism of the tumour itself. Since the 19 kDa albumin fragment was 
present only in trace quantities in the urine of the control subjects, it may be used as a 
complementary urine biomarker to differentiate patients from control. 
 
4.7  SELDI-TOF-MS 
SELDI-TOF-MS is becoming one of the most promising tools for the discovery of 
novel clinical biomarker with the advance and expanding of various types of ProteinChip® 
surfaces that selectively capture specific subgroups of proteins. This is a unique approach in 
which peptides are captured on the target itself by virtue of their chromatographic 
properties. Beside of a good sample preparation and handling technique, the key for a 
successful analysis in SELDI-TOF-MS is also dependent on the ProteinChip® used. There 
are many chips arrays manufactured which are specific for hydrophobic, hydrophilic, 
anionic and cationic proteins. While 2-DE is specifically used to study high molecular 
weight of proteins, SELDI-TOF-MS technique is more sensitive towards low molecular 
weight proteins. Thus, SELDI-TOF-MS technique was used as a complimentary method to 
further analyse the aberrantly expressed proteins in both ovarian carcinoma and cervical 
cancer when compared to the control.  
 
4.7.1 Optimization of the sample preparation 
Originally, in order to obtain optimum low MW protein which is less than 10 kDa, 
the samples were prepared as described in section 2.3.1 with an exception of dialysis step 
where the samples was filtered using two milimicron filtration. However, the obscurity 
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arises when applied to the SELDI-TOF-MS. No peaks were observed although the laser 
energy had been increased up to 3000 nJ. Although several repetitions had been done, the 
unpromising result was obtained. One possibility is that, filtration followed by centrifuged 
and freeze drying did not only concentrate the protein but also the salt.  High concentration 
of salt might have interfered with the binding of the proteins towards the chips although the 
centrifuged samples and filtration did eliminate the big agregates.  
When the urine samples was centrifuged or filtered using two milimicron filtration 
but not concentrated, only peak intensity up to 60 µA for proteins which was less than 5000 
Da were observed, which was dissimilar to that of Roelofen et al. (2007) which managed to 
get 5000 Da with the same protocol. Papale et al., (2007) had demonstrated a better 
spectrum of the urine supernatant but they had to use higher laser intensity of up to 15000 
nJ. However, to increase the laser shoot was not recommended because the used of high 
laser shoot intensity would shorten its life time and affect the efficiency of the laser shoot 
when it has to be used frequently. Therefore, dialysed samples were preferable to be used in 
this study because the removal of the salt gave a better spectrum and more cost effective for 
a longer use of the analyser.  
 
 
4.7.2 ProteinChip® CM10 and Q10 
 
 In this present investigation, ProteinChip® CM10 and Q10 were chosen for the 
screening of aberrantly expressed urinary proteins from patients with ovarian and cervical 
cancer when compared to the control individuals. Evaluations of using various chips with 
different matrix were not done in this study due to the fact that each type of chips was 
expensive and not reliable to be tested out. However, based on the previous study, high 
yield of protein recovery was ensured when tested with CM10 chip in the presence of either 
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SPA or/and CHCA (Roelofen et al., 2007), as compared to IMAC, NP-20, H-50 and H4 
chip arrays. 
 SPA was found to be the best matrix for Q10, H-50 and IMAC-CU and it would 
resolve the low molecular weight mass range of 10000 m/z for CM10, when compared to 
CHCA (Papale et al., 2007). Figure 4 showed that most of the low molecular weight 
proteins were at the acidic side of the 2-DE gel and thus, it was favourable to choose the 
ProteinChip® Q10 with SPA as the matrix solution.  However, in order to ascertain the 
capture of almost all proteins including the basic proteins, which might not have appeared 
on the proteome map, ProteinChip® CM10 with CHCA as the matrix was used. 
 
4.8 Diagnostic decision tree 
4.8.1 Establishment of a diagnostic decision trees from peaks separated by Protein 
Chip® CM10 array or ProteinChip® Q10 array 
After the quality of the decision trees were evaluated (section 3.6.2.1), the final 
decision trees were obtained as shown in figure 11 and 12. Figure 11 showed that the model 
correctly classified ten out of the eleven controls, seven out of the eight ovarian cancers and 
all the eight cervical cancers. The two samples of control and ovarian cancer were 
classified as cervical cancers. Figure 12 showed that the model correctly classified nine out 
of the eleven controls, the eight cervical cancers and eight ovarian cancers except two 
control samples which the model had misclassified them as ovarian cancer. Since the 
sensitivity and specificity of the classification tree was determined from the correctly 
classified diseased and non diseased condition, thus the table as shown in Table 7 and 8 
were developed by using the generated misclassification rate from the BPS software.  
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4.8.2. The implication of low sensitivity, specificity of the test set and broadens peaks 
towards the constructed diagnostic decision trees 
 By referring to Tables 7 and 8, it was notable that the constructed decision tree was 
not good enough to separate the diseased and non diseased condition for the test set. The 
insignificant protein peaks which were used to construct the diagnostic decision trees were 
believed to contribute to the high misclassification rate when they were applied to the cross 
validation method. Referring to Table 6, only m/z 7528.7, 8828.8 and 15802 were 
significant. Although low expression of the protein with m/z 8828.8 found in cervical 
cancer and protein with m/z 7528.78 found in ovarian cancer might have a potential as a 
biomarker, it was hard to decide whether the proteins are good enough to be use as 
biomarker since the poor separation and broadening of the peaks. The broad peaks might 
due to the overlapping proteins and other interferences such as nucleotides. 
Although the classification trees correctly predicted eight cervical cancer patients 
from the control and ovarian cancer groups, making the sensitivity and specificity of the 
classification tress as 100% using ProteinChip® Q10 arrays (Table 8), the classification 
tree was unable to give good classification when cross validation was performed. This most 
probably due to the peaks that were used for classification such as peaks at m/z 5937.1, 
6186.2 and 6349.5, were not significantly detected. 
Interestingly, protein peak at m/z 15802 with a p-value less than 0.05 had a potential 
to be a good biomarker with 100% sensitivity and 89.4% specificity for the learning set. 
Figure 15 demonstrated that the protein was well separated and the expression was obvious 
in the ovarian cancer patient‟s sample. The diagnostic decision tree can be improved by 
having a bigger sample size or to create another decision tree base on the artificial data. The 
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artificial data was created by comparing several variables at a time using linear 
combination splitting base on the equation below (Wu et al., 2006): 
Linear combination split Y= AX1 + BX2 + CX 3 
 
4.8.3 Spectrum profile generated from separation of ProteinChip® CM10 and CHCA 
as the matrix 
When using the CM10 ProteinChip® and CHCA as the matrix, two distinct proteins 
were found to be abnormally expressed in both cancers. The protein that was detected to be 
down regulated only in urine of cervical cancer patients in the present study was revealed in 
figure 13. The protein with m/z of 8828.8 was found to be down-regulated in seven out of 
eight cervical cancer samples. Similarly, protein with the mass of 8427 Da was found to be 
down regulated in the squamous cervical cancer cell by using 2-DE method. The mass 
spectrometry analysis of the protein indicated the protein as chai x, a crystal of the complex 
structure between the human Rhoa and Rho-binding domain of human Rocki (Zhu et al., 
2009). Interestingly, the down regulation of 8828.8 Da protein in the patients with cervical 
cancer might be the similar protein demonstrated previously since the pH of the chai x 
protein is 5.29 and correlate well with chip used in the present study. However, this remains 
to be further proven and the identification of the protein is compulsory to proof the claim. 
 Figure 14 showed that the protein peak with m/z 7528.78 was down-regulated in 
the urine of ovarian carcinoma patients. Since the degree of down-regulation is very 
significant (p-value 0.01), this protein has a potential to be a biomarker. Further study need 
to be done to identify the protein. Interestingly, a study done in 1995 had demonstrated that 
a 7-kDa protein was over expressed in human multidrug-resistant ovarian cancer cells by 
developing a monoclonal antibody that specifically recognise this protein. It was suggested 
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that the over expression of the 7-kDa protein was triggered by the consumption of anti-
cancer drug (Yang et al., 1995).  
Since the patient in the present study have not gone through any drug treatment to 
suppressed the ovarian cancer progression, the level of this protein may remain low in the 
blood and less excreted in the urine and thus, hard to be traced. Another study could be 
done with urine samples from patients with multi-drug resistant ovarian cancer to see 
whether the excretion of the protein is high in the urine. If the protein observed in the 
previous and present study were the same protein, this method and the protein could be 
used as a therapeutic drug monitoring in the future (Jennie et al., 2004). However, 
purification and identification of the protein is needed to be done. It is possible to be done 
since several investigators have reported the successful purification and identification of 
other proteins as markers using tryptic peptide mapping (Rai et al., 2002) and amino acid 
sequencing (Klade et al., 2001). 
 
4.8.4 Spectrum profile generated from separation of Proteinchip® Q 10 and SPA as 
the matrix 
Figure 15 shows aberrantly expressed protein peak with m/z 15802 in the patients 
with ovarian carcinoma. This was found when using the Q10 ProteinChip® and SPA as the 
matrix. Although the protein was relatively large, it was not detected by 2DE. It is probably 
due to the low abundance of the protein in the urine which could only be detected by 
SELDI-TOF-MS.  
In the previous study of early detection in ovarian cancer, the protein peak with m/z 
15867 was found to be elevated in the serum (Kozak et al., 2003; Kozak et al., 2005) and 
identified as beta-hemoglobin protein by using direct mass-spectral profiling (Karpova et 
al., 2010). The beta-hemoglobin protein is a known protein that involved in oxygen 
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transport from the lung to the various peripheral tissues (Ianzer et al., 2006).  Extensive and 
established studies had been done on urine samples (Yoshioka et al., 1986; Jia et al., 1996) 
which had demonstrated the defect in this protein is the cause of beta-thalassemia, beta-
thallassemia dominant inclusion body type (Thein et al., 1990) and sickle cell anemia 
(Finch et al., 1973; Suzuki et al., 1993). 
 The 15802 Da protein found in urine sample in the present study might be beta-
hemoglobin since the separation done in previous study also done on strong anion exchange 
chips. In this present study, the reason for the high level of 15802 Da in the urine of ovarian 
cancer patients is not understood. One possibility is that the elevation of beta-hemoglobin 
was required since more oxygen is required by the cancer cells signifying that the ovarian 
cancer cell undergo cancer progression.  
The decision tree and the distribution of samples had classified nine out of ten 
control samples with intensities more than 10.72 µA at protein peak with m/z 6186 (Figure 
12). Although protein peak with m/z 6186 was detected to be low in ovarian and cervical 
cancer patients when compared to control, the difference was not significant. It was 
reported previously that protein peak at m/z 6195 was down-regulated in the serum of 
ovarian cancer patients by using SELDI-TOF method (Zhang et al., 2006). It is possible 
that these two proteins are the same protein where the down-regulation could be observed 
in both urine and serum. 
 
4.9 Future study  
The maturation of MS technologies has given clinical scientist a powerful analytical 
tool to study human diseases (Aebersold and Mann, 2003). The three aberrantly expressed 
protein peaks found in this study using the SELDI-TOF-MS approach requires to be 
optimized in the gel-based method. Although the identifications of the aberrantly expressed 
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proteins were not determined in this study, the SELDI-TOF-MS technique gave the 
suggestion of the pH and consideration of acrylamide gel percentage to be used in 
investigating and identified the proteins of interest. Thus, these proteins can be extracted 
out by the gel based method and subjected to MALDI-TOF-MS for identification. Another 
way of identification the proteins derived from the SELDI-TOF-MS is by using columns to 
extract the protein of interest and immediately subjected them to LC-MS (Pieper et al., 
2004) or MALDI-TOF-MS for identification. In this case, extraction using column is 
preferable since the 2-DE technique done for screening had limitation and did not 
demonstrate the existence of certain abnormal proteins of interest that can be detected with 
other method such as SELDI-TOF-MS.  
Besides validating these proteins with Western blot technique, further evaluation 
can be done with larger number of samples and much simpler method using the ELISA 
technique in order to reassess the abnormality of these protein expressions in a bigger 
population. Therefore, with more concrete validation and investigation done towards these 
proteins, it is not impossible to apply the proteins as a biomarker by using the ELISA 
technique as a clinical practice purposes in the future for an early diagnosis of the OCa and 
CCa cancers. 
 
4.10 General Conclusion 
 Taken together, the experiments presented here show that ovarian carcinoma and 
cervical cancer causes changes in the urinary proteome map that can be used to 
discriminate between non-cancer control and patients with an early stage of the diseases. 
Although ovarian carcinoma and cervical cancer shared similar pattern of protein excretion 
in the urine, which were CD59, ITIH4 and albumin fragment, less excretion of kininogen-1 
was found only in patients with ovarian carcinoma could differentiate between the two 
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diseases (Pang et al., 2010). Complimentary method using SELDI-TOF-MS had facilitated 
and lead to further findings in searching of potential biomarkes by demonstrating one 
protein peak with relative molecular mass of m/z, 15802 found only in urine of ovarian 
carcinoma patients. Thus, presenting the combine analysis of 2-DE with MS identification 
and SELDI-TOF might improve both sensitivity and specificity for early disease diagnosis. 
It would be insightful to collect urine from larger cohorts of non-cancer control and 
diseased patients and to analyse the peptidome and proteome in depth to fully assess the 
diagnostic potential of these proteomic changes. If the preliminary figures for sensitivity 
and specificity can be improved, it is conceivable that proteomic analysis of urine might 
permit prioritisation of investigation between low probabilities of having tumours and to 
those with higher risk in the future. 
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